<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001945" GROUP_ID="SCHIZ" ID="342599081813171192" MERGED_FROM="" MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Search - how searched WWW and chose 'key authors'.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 14:59:18 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="1077" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Ziprasidone for schizophrenia and severe mental illness</TITLE>
<CONTACT MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="14380" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne-Marie</FIRST_NAME><LAST_NAME>Bagnall</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>A.Bagnall@leedsmet.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Health</DEPARTMENT><ORGANISATION>Leeds Metropolitan University</ORGANISATION><ADDRESS_2>Calverley Street</ADDRESS_2><CITY>Leeds</CITY><ZIP>LS1 3HE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 8124337</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="14380" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne-Marie</FIRST_NAME><LAST_NAME>Bagnall</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>A.Bagnall@leedsmet.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Health</DEPARTMENT><ORGANISATION>Leeds Metropolitan University</ORGANISATION><ADDRESS_2>Calverley Street</ADDRESS_2><CITY>Leeds</CITY><ZIP>LS1 3HE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 8124337</PHONE_1></ADDRESS></PERSON><PERSON ID="7756" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jos</FIRST_NAME><LAST_NAME>Kleijnen</LAST_NAME><EMAIL_1>jos@systematic-reviews.com</EMAIL_1><URL>www.systematic-reviews.com</URL><ADDRESS><ORGANISATION/><ADDRESS_1>NHS Centre for Reviews and Dissemination</ADDRESS_1><ADDRESS_2>University of York, Heslington</ADDRESS_2><CITY>York</CITY><ZIP>YO1 5DD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1904 433647</PHONE_1><FAX_1>+44 1904 433661</FAX_1></ADDRESS></PERSON><PERSON ID="1185118482E26AA201DC7B3ECCC07582" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><LAST_NAME>Leitner</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>mleitner@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>School of Health Sciences</ADDRESS_1><ADDRESS_2>Thompson-Yates Building, Quadrangle, Brownlow Hill</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L69 3GB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 151 794 5288</PHONE_1><FAX_1>+44 151 794 5434</FAX_1></ADDRESS></PERSON><PERSON ID="13477" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><LAST_NAME>Lewis</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>lewisr17@Cardiff.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care and Public Health</DEPARTMENT><ORGANISATION>Cardiff University</ORGANISATION><ADDRESS_1>Centre for Health Sciences / North Wales Clinical School</ADDRESS_1><ADDRESS_2>School of Medicine, Gwenfro Building</ADDRESS_2><CITY>Wrexham</CITY><ZIP>LL13 7YP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1978 727340</PHONE_1><FAX_1>+44 (0)1978 261258</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-21 11:41:29 +0100" MODIFIED_BY="Bethany York" NOTES="&lt;p&gt;Minor update: 23/08/00&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 11:41:29 +0100" NOTES_MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="30" MONTH="8" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="8" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="7" YEAR="2001"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;A substantive amendment was made to this review on 30th August 2000, incorporating unpublished data from Pfizer, the manufacturer of ziprasidone.&lt;/p&gt;"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="18" MONTH="1" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:27:45 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="10" MONTH="11" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-10 15:38:02 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="6" MONTH="10" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-06 15:29:26 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="7" MONTH="7" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-07 21:09:33 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="14" MONTH="4" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 15:42:12 +0200" MODIFIED_BY="Claire Irving">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="30" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Centre for Reviews and Dissemination, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS-R&amp;D Health Technology Assessment Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-11 14:39:40 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-04-23 23:10:45 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-23 23:10:37 +0100" MODIFIED_BY="[Empty name]">Ziprasidone for schizophrenia and severe mental illness</TITLE>
<SUMMARY_BODY MODIFIED="2008-04-23 23:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Pending</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Typical antipsychotic drugs are widely used as the first line treatment for people with schizophrenia. However, the atypical class of antipsychotic drugs are making important inroads into this approach. Atypical is a widely used term used to describe some antipsychotics which have a low propensity to produce movement disorders and raise serum prolactin. There is some suggestion that the different adverse effect profiles of atypical antipsychotic group make them more acceptable to people with schizophrenia. Ziprasidone is one of the newer atypicals with a high serotonin receptor affinity.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of ziprasidone compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 1999), The Cochrane Schizophrenia Group's Register (January 1999), CINAHL (1982-1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1996), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar and Dialog services were searched. References of all identified studies were searched for further trials. Pharmaceutical companies (Pfizer - the manufacturer of ziprasidone - and the manufacturers of all comparator drugs) and first authors of all included trials were contacted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials that compared ziprasidone to other treatments for schizophrenia and schizophrenia-like psychoses were included by independent assessment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Citations and, where possible, abstracts were independently inspected by reviewers, papers ordered, re-inspected and quality assessed. Data were independently extracted.</P>
<P>Data were excluded if loss to follow up was greater than 50%. For homogeneous dichotomous data the risk ratio (RR), 95% confidence interval (CI) and, where appropriate, the number needed to treat (NNT) were calculated on an intention-to-treat basis. For continuous data, weighted mean differences were calculated (WMD). All data were inspected for heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Data for this compound range from very short (one week) studies of the intramuscular preparation, to trials lasting over six months. For measures of mental state ziprasidone seems more effective than placebo (RR 0.8 CI 0.7-0.9) and as effective as haloperidol (RR 0.8 CI 0.7-1). It is less likely than haloperidol to cause movement disorders (RR 0.4 CI 0.2-0.6), but causes more nausea and vomiting (RR 2.1 CI 1.2-3.8). The injected form of the drug causes more pain at the injection site than haloperidol (RR 5.3 CI 1.3-22).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Currently data are limited. Ziprasidone may be an effective antipsychotic with less extrapyramidal effects than haloperidol. It also, however, causes more nausea and vomiting than the typical drugs, and, at present, there is no data suggesting that it is different to other atypical compounds. Well planned, conducted and reported long term randomised trials are needed if ziprasidone is to be accepted into everyday use.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-11 14:39:29 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>In treating people with schizophrenia, choosing the most appropriate, effective and tolerable antipsychotic drug is a key to maximising the usefulness of medication. According to recent treatment guidelines, both conventional/typical and atypical antipsychotic drugs may be reasonable choices in the treatment of schizophrenia (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>, <LINK REF="REF-Geddes-1999" TYPE="REFERENCE">Geddes 1999</LINK>). </P>
<P>Typical antipsychotic drugs, such as haloperidol, chlorpromazine, and trifluoperazine, are widely used as the first line treatment for people with schizophrenia, in the acute as well as in chronic forms of the illness (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>, <LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>). However, the atypical class of antipsychotic drugs, most of which have been formulated relatively recently, are making important inroads into this traditional approach (<LINK REF="REF-Wood-MacKenzie-1998" TYPE="REFERENCE">Wood MacKenzie 1998</LINK>, <LINK REF="REF-Adams-1999" TYPE="REFERENCE">Adams 1999</LINK>). </P>
<P>Atypical is a widely used term to describe some antipsychotics which have a low propensity to produce movement disorders and raised serum prolactin (<LINK REF="REF-Kerwin-1994" TYPE="REFERENCE">Kerwin 1994</LINK>). There is some suggestion that the different adverse effect profiles of the atypical antipsychotic group make them more acceptable to people with schizophrenia (<LINK REF="REF-Casey-1997" TYPE="REFERENCE">Casey 1997</LINK>). Certainly, the adverse effects of the typical drugs, such as movement disorders and sedation, are problematic and can result in poor compliance with treatment (<LINK REF="REF-CWG-1998" TYPE="REFERENCE">CWG 1998</LINK>). </P>
<P>The positive symptoms (delusions, hallucinations, and disordered thinking) of schizophrenia seem more responsive to the typical antipsychotic drugs than the negative symptoms. This latter cluster of symptoms (poverty of speech, lack of motivation, apathy and inability to express emotions (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>)), is very disabling and may respond better to the atypical antipsychotic drugs (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>, <LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>), although this too has not yet been adequately established (<LINK REF="REF-Kane-1996" TYPE="REFERENCE">Kane 1996</LINK>).</P>
<P>Atypical antipsychotics are more expensive than conventional drugs (<LINK REF="REF-Wood-MacKenzie-1998" TYPE="REFERENCE">Wood MacKenzie 1998</LINK>), but it has been suggested that if they do indeed reduce a person's need for inpatient services their use would result in a net reduction of costs (<LINK REF="REF-Buckley-1997" TYPE="REFERENCE">Buckley 1997</LINK>, <LINK REF="REF-Glazer-1997" TYPE="REFERENCE">Glazer 1997</LINK>). </P>
<P>Technical background<BR/>Ziprasidone (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone) is manufactured by Pfizer and has a low affinity for dopamine (D2) receptors and a much higher affinity for serotonin (5HT2) receptors; the serotonin / dopamine ratio is the highest among the atypicals. It has a low affinity for adrenergic (a1) and histaminergic (H1) receptors and may block noradrenaline reuptake. Its half life is about 4 hours after oral administration and 2.9 hours after intravenous administration and its oral bioavailability 59%. At low doses it is a potential anxiolytic/antidepressant (<LINK REF="REF-O_x0027_Connor-1995" TYPE="REFERENCE">O'Connor 1995</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the clinical effects and safety of ziprasidone compared with placebo, typical and other atypical antipsychotics, for treating schizophrenia and related psychoses. </P>
<P>As secondary objectives, it was proposed to investigate:<BR/>1. whether people with schizophrenia described as 'treatment resistant' differed in their response from those whose illness was not designated as such;<BR/>2. whether people having predominantly positive or negative symptoms of schizophrenia were more responsive to ziprasidone than those without this designation; and <BR/>3. whether people experiencing their first episode of schizophrenia differed in their response from those at a later stage of their illness.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 14:39:29 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-11 14:38:38 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials (quasi-randomised studies were excluded).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with the diagnosis of schizophrenia, however diagnosed, were included. Those with schizoaffective disorder, schizophreniform disorder or 'psychotic illness' were also included. If possible, people with dementing illnesses, depression and primary problems associated with substance misuse were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Ziprasidone: any dose.<BR/>2. Placebo.<BR/>3. Any other antipsychotic agent, divided into the atypical (amisulpride, clozapine, loxapine, molindone, olanzapine, quetiapine, risperidone, sertindole, sulpiride, zotepine) and the typical antipsychotics.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-11 14:38:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death - suicide or natural causes</P>
<P>2. Leaving the study early</P>
<P>3. Clinical response<BR/>3.1 Clinically significant response in global state - as defined by each of the studies<BR/>3.2 Average score/change in global state<BR/>3.3 Clinically significant response in mental state - as defined by each of the studies<BR/>3.4 Average score/change in mental state<BR/>3.5 Clinically significant response on positive symptoms - as defined by each of the studies<BR/>3.6 Average score/change in positive symptoms<BR/>3.7 Clinically significant response on negative symptoms - as defined by each of the studies<BR/>3.8 Average score/change in negative symptoms</P>
<P>4. Extrapyramidal side effects<BR/>4.1 Incidence of use of antiparkinson drugs<BR/>4.2 Clinically significant extrapyramidal side effects- as defined by each of the studies<BR/>4.3 Average score/change in extrapyramidal side effects</P>
<P>5. Other adverse effects, general and specific</P>
<P>6. Service utilization outcomes<BR/>6.1 Hospital admission<BR/>6.2 Days in hospital<BR/>6.3 Change in hospital status</P>
<P>7. Economic outcomes</P>
<P>8. Quality of life/satisfaction with care for either recipients or carers measured by directly asking participants<BR/>8.1 Significant change as defined by each of the studies<BR/>8.2 Average score/change in quality of life/ satisfaction</P>
<P>All outcomes were reported for the short term (up to six weeks), medium term (7-26 weeks) and long term (over 26 weeks).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-11 14:39:29 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-11 14:39:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. Biological Abstracts (January 1980 - February 1999) was searched using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (ziprasidone or cp-88059)]</P>
<P>2. The Cochrane Library (Issue 1, 1999) was searched using the phrase:</P>
<P>[ziprasidone or cp-88059]</P>
<P>3. The Cochrane Schizophrenia Group's Register (January 1999) was searched using the phrase:</P>
<P>[ziprasidone or cp-88059 or #42 = 429]</P>
<P>(#42 is the field within this register that contains the intervention code and 429 is ziprasidone.)</P>
<P>4. EMBASE (January 1980 - February 1999) was searched using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ziprasidone or cp-88059 or explode "ZIPRASIDONE"/ all subheadings)]</P>
<P>5. MEDLINE (January 1966 - February 1999) was searched using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ziprasidone or cp-88059]</P>
<P>6. PsycLIT (January 1974 - February 1999) was searched using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (ziprasidone or cp-88059)]</P>
<P>7. LILACS (January 1982 - February 1999) was searched using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (ziprasidone or cp-88059)]</P>
<P>8. PSYNDEX (January 1977 - February 1999) was searched using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (ziprasidone or cp-88059)]</P>
<P>9. CINAHL (1982 - 1999) was searched using the following phrase:<BR/>explode "Psychotic-Disorders"/ all topical subheadings / all age subheadings<BR/>schizo*<BR/>schizo* in ti,ab<BR/>psychoti*<BR/>psychoti* in ti,ab<BR/>psychosis<BR/>psychosis in ti,ab<BR/>psychoses<BR/>psychoses in ti,ab<BR/>chronic*<BR/>sever*<BR/>mental*<BR/>ill<BR/>illness*<BR/>disorder*<BR/>(chronic* or sever*) with mental* with (ill or illness* or disorder*)<BR/>#1 or #3 or #5 or #7 or #9 or #16<BR/>
<BR/>combined with the phrase:<BR/>[and (ziprasidone or cp-88059)]</P>
<P>10. Specific searches for trials of ziprasidone were undertaken in the following data services:</P>
<P>10.1 Datastar service (February 1999)<BR/>Pharmaceutical databases available within this system:<BR/>ADIS Inpharma (indexes 2000 international medical &amp; biomedical journals);<BR/>ADIS LMS drug alerts (indexes 2,300 international medical &amp; biomedical journals );<BR/>IDIS Drug File (indexes 140 English language medical journals);<BR/>PharmLine (indexes 100 journals in drugs and professional pharmacy );<BR/>Pharma Marketing Service (indexes 200 international journals and other non-journal publications).</P>
<P>10.2 Dialog service (February 1999)<BR/>Pharmaceutical databases available within this system:<BR/>CAB Health (international coverage of health journal and non-journal material);<BR/>Conference Papers Index;<BR/>Derwent Drug File;<BR/>Dissertation Abstracts;<BR/>Extramed; Federal Research in Progress (US federally funded research);<BR/>International Pharmaceutical Abstracts (indexes 800 pharmaceutical and medical journals);<BR/>JICST-EPLus (Japanese Science and Technology);<BR/>Mental Health Abstracts;<BR/>NTIS (national Technical Information Service);<BR/>Pascal;<BR/>Pharmaprojects;<BR/>USP-DI - Drug information for the health care professional.</P>
<P>These services were searched using the phrase:</P>
<P>((schizo$ or psychotic$ or psychoses or psychosis or ((chronic$ or sever$) near2 mental$ near2 (ill$ or disorder$)) and (trial$ or random$ or (singl$ or doubl$ or trebl$ or tripl$) near (blind$ or mask$) or ((placebo or standard) adj treatment) or study or studies or rct$ or crossover$ or control or controlled or controls) and (ziprasidone or cp-88059)</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-11 14:39:29 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference lists<BR/>All references of articles selected were searched for further relevant trials.</P>
<P>2. Authors of studies<BR/>The reviewers contacted first authors of all included studies to ask for additional studies and, when necessary, to clarify data.</P>
<P>3. Pharmaceutical company<BR/>The reviewers contacted Pfizer Pharmaceuticals and manufacturers of all comparator drugs to obtain data on unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>The inspection of the citations identified in the search outlined above was performed independently by two reviewers (AMB and RL). Potentially relevant abstracts were identified and full papers ordered and reassessed for inclusion and methodological quality. Any disagreement was discussed and reported.</P>
<P>2. Assessment of quality<BR/>Trials were allocated to three quality categories, as described in the Cochrane Reviewer's Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>) by each reviewer, again, working independently. When disputes arose as to which category a trial was allocated, again, resolution was attempted by discussion. When this was not possible, and further information was necessary, data were not entered into the analyses and the study was allocated to the list of those awaiting assessment. Only trials in Category A or B were included in the review. </P>
<P>3. Data management<BR/>3.1 Data extraction<BR/>This was performed independently by two reviewers (AMB, RL) and, where further clarification was needed, the authors of trials were contacted to provide missing data.</P>
<P>3.2 Intention to treat analysis<BR/>Data were excluded from studies where more than 50% of participants in any group were lost to follow up (this does not include the outcome of 'leaving the study early'). In studies with less than 50% dropout rate, people leaving early were considered to have had the negative outcome, except for the event of death. The impact of including studies with high attrition rates (25-50%) was analysed in a sensitivity analysis. If inclusion of data from this latter group did result in a substantive change in the estimate of effect their data were not added to trials with less attrition, but presented separately. </P>
<P>4. Data analysis<BR/>4.1 Binary data<BR/>For binary outcomes a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI) was calculated. The number needed to treat statistic (NNT) was also calculated. If heterogeneity was found (see section 5) a random effects model was used.</P>
<P>4.2 Continuous data<BR/>4.2.1 Skewed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards are applied to all data before inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale starts from zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution) (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied to them; (c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above in (b) was modified to take the scale starting point into account. In these cases skewness was deemed to be present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score. <BR/>If data were non-normally distributed (skewed) they were not subject to a meta-analysis, but are reported in the 'Additional data' tables.<BR/> <BR/>4.2.2 Summary statistic: for continuous outcomes a weighted mean difference (WMD) between groups was estimated. Again, if heterogeneity was found (see section 5) a random effects model was used.</P>
<P>4.2.3 Valid scales: continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal and the instrument was either a self report or completed by an independent rater or relative (not the therapist). </P>
<P>4.2.4 Endpoint versus change data: where possible endpoint data were presented and if both endpoint and change data were available for the same outcomes then only the former were reported in this review.</P>
<P>5. Test for heterogeneity<BR/>A Chi-square test was used, as well as visual inspection of graphs, to investigate the possibility of heterogeneity. A significance level less than 0.10 was interpreted as evidence of heterogeneity. If this was found the data were re-analysed using a random effects model to see if this made a substantial difference. If it did, the studies responsible for the heterogeneity were summated and presented separately, and possible reasons for the heterogeneity were explored.</P>
<P>6. Addressing publication bias <BR/>Data from all included studies were entered into a funnel graph (trial effect against trial size) in an attempt to investigate the likelihood of overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>7. Sensitivity analyses<BR/>The effect of including studies with high attrition rates was analysed in a sensitivity analysis. It also was hoped to investigate whether there were differences among:<BR/>a. people with schizophrenia described as 'treatment resistant' and those whose illness was not designated as such;<BR/>b. people having predominantly positive or negative symptoms of schizophrenia and those without this designation; and <BR/>c. people experiencing their first episode of schizophrenia and those at a later stage of their illness.</P>
<P>8. General<BR/>Where possible, reviewers entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for ziprasidone.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of studies please see Included and Excluded Studies table. </P>
<P>1. Excluded studies<BR/>Over 20 studies were excluded. Five were review articles, three were in vitro or animal studies, six studied the physiological effects of ziprasidone on healthy volunteers and nine were clinical trials of ziprasidone that did not use a control group. <LINK REF="STD-Hagger-1997" TYPE="STUDY">Hagger 1997</LINK> (n=11) was a relevant randomised trial, undertaken by researches independent of industry funding, but presented only as a conference abstract and did not contain enough information to allow inclusion. </P>
<P>2. Awaiting assessment<BR/>No studies are awaiting assessment.</P>
<P>3. Ongoing studies<BR/>Three studies were reported as ongoing in the retrieved literature - all are held on file at Pfizer (the manufacturers of ziprasidone) but have not been published. A further two studies were reported as ongoing (personal communication from Pfizer) but the reviewers have not seen any data relating to these trials. </P>
<P>4. Included studies<BR/>All seven included trials were randomised, five double blind, and two (the intramuscular studies) were single blind. Three of the included double-blind studies were full journal articles, the remainder being abstracts and posters from conference proceedings which give very little information on outcomes. Seven of the studies had company employees from Pfizer as named authors. The reviewers have written to all the authors of included studies for further information and have spoken to Pfizer, the manufacturers of ziprasidone, for clarification of some issues.</P>
<P>4.1 Length of trials<BR/>Two of the studies (those which used intramuscular preparations of ziprasidone) were of very short duration, lasting only one week, and three of the studies were of 'short duration', as defined by the protocol for this review, lasting between four and six weeks. Two were long-term, one lasting six months and another year. The long-term studies have been published as conference posters (with limited data), not as full papers. </P>
<P>4.2 Participants<BR/>All studies met operationalised diagnoses of schizophrenia and schizoaffective disorder by Diagnostic and Statistical Manual criteria. Those with schizoaffective disorder were included in all but one study (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>). The two studies of intramuscular ziprasidone included all 'acutely psychotic' patients, including those with bipolar and delusional disorders. <LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>, <LINK REF="STD-Goff-1998" TYPE="STUDY">Goff 1998</LINK> and <LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK> (the three full papers) only included those with acute exacerbation of chronic or sub-chronic illness, <LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK> and <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> (both long-term studies) included only those with chronic stable schizophrenia. In the <LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>, <LINK REF="STD-Goff-1998" TYPE="STUDY">Goff 1998</LINK> and <LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK> studies, patients were not previously resistant to neuroleptic treatments, but, by their ratings on BPRS or PANSS, were quite ill. Organic problems and those who were prone to abuse substances were largely excluded.</P>
<P>4.3 Setting<BR/>Most participants in the included short-term studies were in hospital at the beginning of the study. All of those in the <LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK> study were in hospital. In the six-month study all participants were attending outpatient clinics. </P>
<P>4.4 Study size<BR/>
<LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK> was the largest study with 306 participants, <LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK> had 302, <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>, 301 and <LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK> randomised 294 people. Only <LINK REF="STD-Goff-1998" TYPE="STUDY">Goff 1998</LINK>, with 90 participants, reported a power calculation to demonstrate a 25% difference between groups on the BPRS with 80% power if 20 people were included in each group.</P>
<P>4.5 Interventions<BR/>Three trials were placebo controlled and one used haloperidol 15mg as a comparator (<LINK REF="STD-Goff-1998" TYPE="STUDY">Goff 1998</LINK>). Three studies (including both the intramuscular studies) used a flexible dose of haloperidol as a control. Doses of ziprasidone ranged from 4mg/day to 160mg/day.</P>
<P>4.6 Outcomes<BR/>4.6.1 Improvement: definition of improvement consisted of a score of 1 or 2 on the CGI-I scale (<LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>, <LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>), a 30% or greater decrease in PANSS (<LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>), a 20% decrease in PANSS negative subscale score (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>), or a 30% decrease in BPRS total score (<LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>).</P>
<P>4.6.2 Missing outcomes: despite the inclusion of two long-term studies in outpatients, there are no data relating to outcomes such as hospital admission or costs. None of the included trials, whether short or long term, focused on clinically relevant outcomes such as quality of daily functioning, 'employed', 'trouble with the police', satisfaction with care. No study reassured the reader as regards mortality.</P>
<P>4.6.3 Continuous data: details of the scales that supplied usable data for this review are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the 'Included studies' section. </P>
<P>Global state<BR/>1. Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement.</P>
<P>2. Global Assessment Scale - GAS (<LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>) <BR/>Used to evaluate the overall functioning of a person during a specified time period in terms of psychological well being or sickness. Time period assessed is generally one week prior to evaluation. Scale covers entire range of severity and can be used in any situation or study where an overall evaluation of the severity of the illness or degree of health is needed. </P>
<P>3. Global Assessment of Functioning Scale - GAF Scale.<BR/>Provides a graduated continuum (varying between zero and 100) from a psychological or psychiatric sickness health. </P>
<P>Mental state<BR/>1. Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>).<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms. The BPRS-positive cluster comprises of four items, which are conceptual disorganisation, suspiciousness, hallucinatory behaviour, and unusual thought content. The BPRS-negative cluster comprises of only three items, which are emotional withdrawal, motor retardation, and blunt affect. </P>
<P>2. Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>). <BR/>This six-point scale gives a global rating of the following negative symptoms; alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.</P>
<P>3. Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>PANSS originated as a method for evaluating positive, negative, and other symptom dimensions in schizophrenia. The scale has 30 items, and each item can be defined on a seven-point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates low levels of psychotic symptoms.</P>
<P>4. Montgomery Asberg Depression Rating Scale - MADRS (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>)<BR/>developed using a 65-item comprehensive psychopathology scale were to identify the 17 most commonly occurring symptoms in primary depressive illness. Ratings on 10 items, with higher score indicating poor outcome. Maximum score is 30.<BR/> <BR/>Side effects: extrapyramidal<BR/>1. Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder. The AIMS can be used to assess some short-term movement disorders such as tremor.</P>
<P>2. Simpson Angus Scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism. </P>
<P>3. Barnes Akathisia Scale (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>Akathisia is a short term, drug-induced movement disorder. The scale comprises of items rating the observable, restless movements that characterise akathisia, the subjective awareness of restlessness, and any distress associated with the condition. These items are rated from zero - normal to three - severe. In addition, there is an item for rating global severity (from zero - absent to five - severe). A low score indicates low levels of akathisia. </P>
<P>Side effects: general <BR/>COSTART Terms (<LINK REF="REF-COSTART-1990" TYPE="REFERENCE">COSTART 1990</LINK>)<BR/>This is a list drawn up by the US Food and Drug Administration in order to help consistent description of adverse reactions. As far as the reviewers understand, it is not a scoring system.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Randomisation<BR/>All included studies fell into quality category B as it was not clear exactly how randomisation had been conducted. The reader, therefore, was not assured that the introduction of biases was minimised at this crucial stage. It has been shown that poor reporting of randomisation increases the odds of presenting 'significant' outcomes (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>, <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
<P>Blinding to interventions and outcomes<BR/>No studies clearly described adequate precautions for blinding of treatment. In the two trials of intramuscular ziprasidone, treatment was not given blind for practical reasons. No included trial tested the adequacy of the blindness of those rating outcomes. </P>
<P>Follow-up<BR/>In five studies, more than one quarter of participants left the study before it ended. The intramuscular studies had a lower rate of attrition (12% or less), probably due to their short duration, and, in one of the long term studies (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>), attrition was incompletely reported (see Results). Exactly why people decided to leave, or were excluded was not, however, explicit. Once participants leave a study, unless the trialists continue to follow and collect data, assumptions have to be made about outcome. Five studies stated that they analysed data on an intention-to-treat basis using the last observation carried forward. This practice may well overestimate the effects of treatment. Whatever the management of lost data, interpretation of results with large degrees of attrition must be undertaken with caution.</P>
<P>The barely adequate reporting of randomisation, possible lack of double blindness for these outcomes and unclear reasons for loss to follow up would suggest that all estimates of effect of the experimental intervention are prone to exaggeration (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The literature search yielded 94 citations, of which 50 were retrieved for further assessment. Of these, 32 papers (23 studies) were excluded from the review and 18 papers (seven studies) were included. Contact with Pfizer yielded no additional studies. Instead the reviewers were given additional information on design and outcomes of included studies and were also told of three ongoing studies but given few details of these.</P>
<P>COMPARISON 1. ZIPRASIDONE versus PLACEBO</P>
<P>1. Global effect<BR/>Two studies (<LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>, <LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>) defined lack of response as CGI-I scores of &gt;2. Ziprasidone was superior to placebo in these two short studies (RR 0.85 95% CI 0.8-0.96). <LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK> also reported CGI-S change scores. There was no clear difference between ziprasidone and placebo at dose 40mg/day (MD -0.2 CI -0.6 to 0.2) or at 120mg/day (MD -0.4 CI -0.81 to 0.01). <LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK> reports a statistically significant difference in CGI-S scale at all doses in the long term and at 160mg in the short term also, in favour of ziprasidone. A statistically significant difference is also seen in the Global Assessment of Functioning Scale between groups in favour of ziprasidone at one year (MD -5.14, CI -11.7 --5.1).</P>
<P>2. Mental state<BR/>
<LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK> defined response as 30% decrease in PANSS, and <LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK> as a 30% decrease in BPRS total score. When summated and analysed as 'no response' ziprasidone is avoids this outcome more frequently than placebo (RR 0.83 CI 0.7-0.9). The outcome of 'impending relapse', defined as a CGI-I score of &gt;5 and/or a score of &gt;5 on PANSS items P7 (hostility) or G8 (uncooperativeness) on two successive days, was reported by <LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK> at six months. Again ziprasidone was superior to placebo (RR 0.71 CI 0.6-0.9, NNT 5 CI 3-13). </P>
<P>People receiving ziprasidone were less likely to need additional lorazepam (prescribed for additional tranquillisation) than those allocated placebo (RR 0.92 CI 0.8-0.98, NNT 13 CI 7-49). </P>
<P>
<LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK> reported BPRS total change scores. There was no clear difference between ziprasidone (40mg/day) and placebo but at 120mg/day ziprasidone was more effective than placebo (MD -6.00 CI -11.3 to -0.7). There was no evidence of a difference between placebo and ziprasidone at either dose when measured by rating BPRS core items or SANS change scores. </P>
<P>At one year (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>) BPRS total and core endpoint scores and PANSS total endpoint scores favoured ziprasidone over placebo for all doses. Negative symptoms (PANSS negative subscale) favoured ziprasidone over placebo in the long term.</P>
<P>3. Leaving the study early<BR/>In the short term studies (<LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>, <LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>) 46% of trial participants left the trials before completion. Overall there were no differences between groups (RR 0.85 CI 0.7-1.1). but when lack of efficacy was cited as the reason for attrition (<LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>) the ziprasidone group retained more participants than the placebo group (RR 0.6 CI 0.4-0.9, NNT 5 CI 3-13). When adverse events were blamed for loss to follow up no differences were seen in the rates between those allocated ziprasidone and people on placebo in the short or long term.</P>
<P>4. Side effects<BR/>Two short term studies (<LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>, <LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>) and one long-term study (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>) report the outcome 'any adverse event'. No differences were seen for this outcome across either time scale between placebo and ziprasidone at any dose. The frequency of dizziness was reported in the two short term studies and there was no clear difference between placebo and ziprasidone at any dose. The low frequency of nausea, vomiting, dyspepsia, diarrhoea and constipation was reported in both short term studies (<LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>, <LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>). Again there were no significant differences in the frequencies of these adverse effects between groups. There were also no differences in the prevalence of various extrapyramidal effects in people receiving ziprasidone or placebo in either the short or long term. More people in the group receiving ziprasidone required anti-parkinsonian medication than in the placebo group (RR 1.7 CI 1-2.7, NNH 11 CI 6-67). Ziprasidone caused increased sedation in one study (<LINK REF="STD-Daniel-1999" TYPE="STUDY">Daniel 1999</LINK>) RR 3.50, CI 1.4-8.6, but not in the other (<LINK REF="STD-Keck-1998" TYPE="STUDY">Keck 1998</LINK>). A list of other adverse effects were reported but none showed differences between ziprasidone and placebo. In the long term (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>) no difference in body weight was seen between ziprasidone and placebo groups.</P>
<P>5. Missing outcomes<BR/>No studies reported on service utilisation, economic outcomes, quality of life or satisfaction with care.</P>
<P>COMPARISON 2. ZIPRASIDONE versus TYPICAL ANTIPSYCHOTICS</P>
<P>1. Global effect<BR/>No clear difference was seen between ziprasidone and typical antipsychotic drugs on the CGI-S scale over six months (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>).</P>
<P>2. Mental State<BR/>One study using intramuscular ziprasidone versus haloperidol for the immediate management of those with schizophrenia (<LINK REF="STD-Brook-1998" TYPE="STUDY">Brook 1998</LINK>), reported BPRS change scores, and found in favour of ziprasidone (MD -3.00 CI -4 to -2.5). <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>, however, in a long term study, pre-stated a cut-off point of a 20% decrease in the PANSS score to be a clinically important response. The findings, comparing ziprasidone and haloperidol, were equivocal (RR 0.86 CI 0.7-1). The same study also reported relapse in specific symptoms (psychosis, hallucinations) and, again no clear differences were found or suggested by the data. No differences were seen in PANSS or BPRS endpoint scores in the same study at six months or on the PANSS negative subscale.</P>
<P>3. Leaving the study early <BR/>The numbers leaving the studies early in the long term study (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>) were 26% (38/148) in the ziprasidone group and 24% (36/153) in the haloperidol group (RR 1.1 CI 0.7-1.6). This percentage represents a considerably lower attrition rate than that seen with some other atypical antipsychotics such as olanzapine (<LINK REF="REF-Duggan-1999" TYPE="REFERENCE">Duggan 1999</LINK>) and quetiapine (<LINK REF="REF-Srisurapanont-1998" TYPE="REFERENCE">Srisurapanont 1998</LINK>).</P>
<P>4. Side-effects<BR/>4.1 Any adverse event<BR/>Two studies, one investigating the very short term effects on acutely ill people (<LINK REF="STD-Brook-1998" TYPE="STUDY">Brook 1998</LINK>) and one looking at long term effects (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>) report data on "any adverse event". There was clear difference between ziprasidone and haloperidol for either the immediate term (RR 0.8 CI 0.6-1.1) or over six months (RR 0.9 CI 0.8-1.0). </P>
<P>4.2 Cardiovascular<BR/>One study reported ECG data (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>) although four state that ECG was recorded. <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> reported that no clinically relevant changes in ECG were seen in either group and that no participant had a QTc interval greater than 500ms or had an increase in QTc interval of 20% or above. Data are given for the outcome 'dizziness', a somewhat vague symptom which is sometimes attributed to orthostatic hypotension (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> and <LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK>). Again, because one study was very short term (<LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK>) and one long term (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>) it was not thought appropriate to pool the results. There was no difference between ziprasidone and haloperidol in either study.</P>
<P>4.3 Gastrointestinal<BR/>One short-term study (<LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK>) and one long-term trial (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>) reported for events of nausea and vomiting. Both found that ziprasidone was significantly more likely to be associated with nausea and vomiting than haloperidol (<LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK> RR 3.6 CI 1.8-7, NNH 5 CI 4-8; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> RR 2.1 CI 1-4, NNH 9 CI 5-33), however there was no statistically significant difference when ziprasidone was compared to placebo.</P>
<P>4.4 Movement disorders<BR/>Ziprasidone produced less akathisia than haloperidol both in the immediate term (RR 0.3 CI 0.2-0.6, NNH 8 CI 5-18) and in the long term (RR 0.3 CI 0.1-0.7, NNH 9 CI 5-21). The experimental drug also produced less acute dystonias (RR 0.4 CI 0.2-0.9, NNH 16 CI 9-166) and less hypertonia than haloperidol (<LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK>, RR 0.2 CI 0.1-0.6, NNH 12 CI 7-48; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> RR 0.3 CI 0.1-0.99, NNH 19 CI 10-208). <BR/>Even in those specific movement disorder that did not reach a conventional level of statistical significance all ziprasidone data favoured it over haloperidol. This suggestion that ziprasidone causes fewer movement disorder effects than typical drugs is supported by data reporting the use of additional anticholinergic medication from <LINK REF="STD-Brook-1998" TYPE="STUDY">Brook 1998</LINK>, which found in favour of ziprasidone (RR 0.3 CI 0.2-0.6, NNH 3 CI 2-6). <LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK> also reported that benztropine was required by substantially more patients allocated to haloperidol than those in the ziprasidone group but not enough data were given to put these results into the analysis.</P>
<P>4.5 Sleep problems<BR/>There is no suggestion that differences exist between ziprasidone and haloperidol for the outcomes of insomnia or somnolence.</P>
<P>4.6 Other side effects<BR/>Dry mouth, asthenia, anxiety and depression were found to be equally prevalent in both groups. In one of the intramuscular studies (<LINK REF="STD-Swift-1998" TYPE="STUDY">Swift 1998</LINK>) injection site pain was more prevalent in the ziprasidone than the haloperidol group (RR 5.3 CI 1.3-22, NNH 12 CI 7-27). Ziprasidone may be more likely than haloperidol to cause headache (RR 2.12, CI 1.02-4.4).</P>
<P>5. Weight<BR/>
<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> reports similar weight gain in ziprasidone and haloperidol groups, with women gaining slightly more weight (0.8 kg in the ziprasidone group and 0.9kg in the haloperidol group) than men (0.3 kg in each group). Not enough data was given to include these results in the analysis.</P>
<P>6. Missing outcomes<BR/>No studies reported on service utilisation, economic outcomes, quality of life or satisfaction with care.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Generalisability<BR/>Most studies were set in North America and randomised those with operationally diagnosed disorders uncomplicated by additional problems. Most participants in studies that lasted longer than one week, had chronic schizophrenia and specifically excluded those with acute exacerbation. Those in the short term intramuscular ziprasidone studies were experiencing acute exacerbations of schizophrenia. Most studies excluded people who had previously been resistant to neuroleptic treatment. The three studies which have been published as full papers applied stringent inclusion criteria relating to baseline BPRS or PANSS measurements. Such practices must limit the generalisability of the review's findings. </P>
<P>Limited data<BR/>The collection and quality of reporting of data is disappointing. Most trials report only one to six week outcomes. <LINK REF="STD-Goff-1998" TYPE="STUDY">Goff 1998</LINK> was four weeks, but the rate of attrition was over the 50% cut off, allowing the reviewers to only include data for the outcome of 'leaving the study early'. <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> was a 28-week study but, as yet, has only been published as conference abstract, as was the one year study (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>). Much data were inadequately reported in these abstracts for use in this review. Particularly disappointing was the reporting of <LINK REF="STD-Hagger-1997" TYPE="STUDY">Hagger 1997</LINK> which was not only a long term study, but was the only study to compare ziprasidone to another atypical drug (risperidone). This small study was reported in such as way that even 'leaving the study early' was impossible to include in the analyses. Pfizer, the manufacturers of ziprasidone, have informed the reviewers that <LINK REF="STD-Hagger-1997" TYPE="STUDY">Hagger 1997</LINK> is part of a larger multicentre comparison of ziprasidone and risperidone but have not been given any details of this larger study. No studies reported on service utilisation, economic outcomes, quality of life or directly on satisfaction with care. Most of the trial reports were published after the year of the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>), that encouraged high standards of trial reporting, yet these trials only achieved a quality rating of 'B' (poor) in their published form, with additional information given directly to the reviewers by Pfizer elevating them to a quality rating of 'A' (good).</P>
<P>Sensitivity analysis and publication bias<BR/>It was not possible to undertake either a funnel graph or a sensitivity analyses for people with schizophrenia described as 'treatment resistant', people having predominantly positive or negative symptoms of schizophrenia and people experiencing their first episode of schizophrenia. The very small number of full studies with useful data, the exclusion of patients who were treatment-resistant and the inclusion of mainly those with chronic schizophrenia as opposed to first episode schizophrenia precluded such activities. It was also impossible to undertake a sensitivity analysis investigating the effect of excluding studies with attrition rates from 25-50%. All studies which reported attrition rate had losses to follow up over 25% except for the very short term studies that were not appropriate to combine with the longer trials.</P>
<P>COMPARISON 1. ZIPRASIDONE versus PLACEBO</P>
<P>1. Global effect<BR/>There are limited useable data on outcomes of global functioning but those that exist do tend to favour ziprasidone over placebo. The NNT is about 8 (CI 5-28) suggesting that, like all other antipsychotic drugs, ziprasidone, while being a welcome treatment, is not a revolution in care.</P>
<P>2. Mental state<BR/>The mental state findings are very consistent with ziprasidone being more effective than placebo in improving almost every way of measuring this outcome. Again the NNT (7 CI 5-21- calculated from the outcome of 'No response') is a salutary reminder that, whilst being an effective drug, data relating the effects of ziprasidone on mental state do not suggest that it is dramatically different from other compounds. Ziprasidone seemed to be more effective than placebo in relieving negative symptoms at one year (<LINK REF="STD-Arato-1997" TYPE="STUDY">Arato 1997</LINK>), however it was no more effective than haloperidol at six months in another study (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>)</P>
<P>3. Leaving the study early<BR/>Over 40% of people left ziprasidone studies before trial completion, although fewer people left the ziprasidone group than the placebo group due to lack of efficacy. All data in this comparison, by necessity, incorporates very considerable assumptions due to high attrition. For example, although the mental state and global effect outcomes do seem to favour ziprasidone, building in different assumptions about those who left early, not that they all had a negative outcome (see 'Methods') can considerably change the results. All data in this comparison are founded on assumptions, the manipulation of which can greatly change the overall results. </P>
<P>4. Side effects<BR/>There were no significant differences between those receiving ziprasidone and those allocated placebo in rates of any adverse event - including movement disorder. More of those taking ziprasidone received anti-parkinsonian medication, which may go some way towards explaining the equivalence between ziprasidone and placebo in rates of movement disorder. Ziprasidone may cause more sedation than placebo. There were no indications that ziprasidone increases weight.</P>
<P>5. Missing outcomes<BR/>Despite the inclusion of a long term study, no data was collected on patient quality of life or satisfaction with treatment or care. Data on service utilisation and social and economic outcomes was also missing. That such outcomes, of key importance to recipients of care, clinicians and managers/policy makers, are absent suggests that these studies were not undertaken primarily to convince these groups of the value of ziprasidone. </P>
<P>COMPARISON 2. ZIPRASIDONE versus TYPICAL ANTIPSYCHOTICS</P>
<P>1. Global improvement.<BR/>It is disappointing, and surprising, that no studies measured this important outcome.</P>
<P>2. Mental State<BR/>When response was defined as a 20% decrease in the PANSS score, ziprasidone was as effective as haloperidol. It has been suggested that such a modest change in PANSS is not often clinically meaningful (<LINK REF="REF-Kennedy-1999" TYPE="REFERENCE">Kennedy 1999</LINK>) but ziprasidone's equivalence to haloperidol is reassuring. Ziprasidone did not seem to be any more effective in alleviating negative symptoms than haloperidol at six months (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>).</P>
<P>3. Leaving the study early<BR/>Leaving the study early may be viewed as a measure of how acceptable the treatment is to the people receiving it - in this case ziprasidone was found to be equal to haloperidol in acceptability. In addition, that only about 25% of people were lost to follow up, even in the longer studies (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>) should be encouraging to trialists disheartened by greater loss over shorter time periods.</P>
<P>4. Side-effects<BR/>Overall, people receiving ziprasidone did not have significantly different rates of most adverse events than those receiving haloperidol. Rates of agitation, dizziness, sleep problems, dry mouth, asthenia, headache, anxiety and depression were low and similar in those receiving ziprasidone and people allocated placebo. People taking ziprasidone experienced significantly more nausea and vomiting than those taking haloperidol, however they did not experience more nausea and vomiting than people taking placebo. It has been suggested that antipsychotic drugs usually 'mask' nausea and vomiting associated with schizophrenia and that perhaps ziprasidone does not have this masking effect (rather than actually causing the nausea and vomiting). In this case it would not be so much an adverse effect as failure to exert a beneficial effect.</P>
<P>Movement disorders were less common those allocated ziprasidone compared to the haloperidol control group. It would have been reassuring if the "author-defined EPS" had been reported as being defined before seeing the data. If they were defined post hoc the potential for bias is considerable. Injection site pain was reported more often in people receiving intramuscular ziprasidone than in people allocated to the intramuscular haloperidol group. It has been suggested (personal communication from Pfizer) that this may be due to the addition of extra solvents to the ziprasidone preparation.</P>
<P>COMPARISON 3. ZIPRASIDONE versus ATYPICAL ANTIPSYCHOTICS</P>
<P>The one study which compared ziprasidone to an atypical antipsychotic, risperidone, (<LINK REF="STD-Hagger-1997" TYPE="STUDY">Hagger 1997</LINK>) reported on only 11 patients, six of whom left the study early, making the attrition rate above 50%. The small amount of data published in this conference poster were impossible to use in this review. Data from such a small sample would have been difficult to justify including even if the attrition rate had been less than 50% as the possibility of detecting a difference where there was none (a type II error) increases as sample size, and study power, decrease. The manufacturers of ziprasidone (Pfizer) have informed the reviewers that this study is a report from one centre of a large multicentre study but as yet this study remains unpublished and the reviewers have been given access to any further data.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. Those with schizophrenia<BR/>Limited data currently available suggests that ziprasidone is more effective than placebo and as clinically effective and acceptable as haloperidol for those with schizophrenia. It is less likely than haloperidol to cause movement disorders but may possibly cause more nausea and vomiting. The injected form of the drug may cause more pain at the site of injection than haloperidol.</P>
<P>2. Clinicians<BR/>Useful data on this drug are limited and more studies should be undertaken if ziprasidone is to be recommended for sub-groups of those with schizophrenia such as people with negative symptoms. The possible adverse effect of nausea/vomiting may be of concern as this may have implications for compliance in the real world outside of trials (although no difference was seen between ziprasidone and placebo in placebo controlled trials). No informative studies have been published which compare the effects of ziprasidone with other atypical antipsychotics, so no recommendations can be made at this stage about the advantages or disadvantages of prescribing ziprasidone over other atypical antipsychotic medication.</P>
<P>3. Managers or policy makers<BR/>No data relating to service utilisation, care management or economics were reported. If ziprasidone is to gain wide acceptance future studies should address these deficiencies.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>General<BR/>Clear and strict adherence to the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>) for all outcomes would have resulted in this review being more informative. Denominator data were not always clearly presented and some results were described as 'significant' or not, but numbers were not reported, especially in the conference posters. Authors should present raw data. If p-values are used, the exact value should be reported as well as the test employed. If data are presented in a graph, the exact numbers represented by the graph should also be reported.</P>
<P>Specific<BR/>Better planned, conducted and reported randomised controlled trials are needed to run over longer periods and to address clinically and socially relevant outcomes. Data relating to global functioning, mental state and behaviour need replication and expansion. High quality trial-derived data about hospital admission, satisfaction with care, social functioning, family burden and employment would be of great interest. More trials comparing ziprasidone to typical comparators and, especially, to atypical comparators such as risperidone and olanzapine are needed urgently. Further trials should address the gastrointestinal problems potentially associated with ziprasidone. Useful cost effectiveness data must be a research priority.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-11 14:39:37 +0000" MODIFIED_BY="[Empty name]">
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-11-11 14:39:40 +0000" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Anne-Marie Bagnall - protocol development, undertook searches, selected and acquired studies, extracted data, summated data, produced report.</P>
<P>Jos Kleijnen - protocol development, interpretation of results, input into final report.</P>
<P>Maria Leitner - finding funding, initial input into the protocol and searches.</P>
<P>Ruth Lewis - protocol development, undertook searches, selected and acquired studies, extracted data, summated data, produced report.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>Cochrane Schizophrenia Group internal peer review complete (see Module).<BR/>External peer review scheduled.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-11 14:59:18 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-21 11:44:55 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-21 11:44:55 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Arato-1997" NAME="Arato 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Arato M, O'Connor R, Meltzer H, Bradbury J</AU>
<TI>Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia</TI>
<SO>10th European College of Neuropsychopharmacology Congress</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brook-1998" NAME="Brook 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Brook S, Krams M, Gunn KP, Ziprasidone IM Study Group</AU>
<TI>The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute, non-organic psychosis</TI>
<SO>151st American Psychiatric Association Meeting</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Daniel-1999" MODIFIED="2008-10-21 11:44:55 +0100" MODIFIED_BY="[Empty name]" NAME="Daniel 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-21 11:44:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel D, Reeves K, Harrigan EP</AU>
<TI>The efficacy and safety of ziprasidone 80mg/day and 160mg/day in schizophrenia and schizoaffective disorder</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>204</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT603"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayan M, Ziprasidone Study Group</AU>
<TI>Ziprasidone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a six-week placebo-controlled trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>5</NO>
<PG>491-505</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrigan EP, Reeves K</AU>
<TI>The efficacy and safety of two fixed doses of ziprasidone in schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>3</NO>
<PG>456</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT551"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keck PE, Reeves KR, Harrigan EP, Laminarayan M, Ziprasidone Study Group</AU>
<TI>Ziprasidone reduces overall psychopathology and symptoms of depression in the acute treatment of schizoaffective disorder</TI>
<SO>American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reeves K, Harrigan EP</AU>
<TI>Two fixed doses of ziprasidone - efficacy and safety</TI>
<SO>Xth World Congress of Psychiatry, Madrid, Spain</SO>
<YR>Aug 23-28, 1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT250"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reeves KR, Harrigan EP</AU>
<TI>The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaffective disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6 Suppl 3</VL>
<PG>201</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT606"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Goff-1998" NAME="Goff 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;full paper. Attrition 51%, excluded from most analyses.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN</AU>
<TI>An exploratory Haloperidol-controlled dose-finding study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>4</NO>
<PG>296-304</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT374"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>O'Connor R, Harrigan E, Heym J, Ko G, Chandler L</AU>
<TI>The efficacy and safety profile of a new antipsychotic, ziprasidone</TI>
<SO>8th European College of Neuropsychopharmacology Congress</SO>
<YR>1995</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT605"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hirsch-1999" NAME="Hirsch 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hirsch S, Power A, Kissling W</AU>
<TI>A 28-week comparison of flexible-dose ziprasidone with haloperidol in outpatients with stable schizophrenia</TI>
<SO>World Congress of Psychiatry, Hamburg</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Keck-1998" NAME="Keck 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrigan E, Morrissey M, Ziprasidone Working Group</AU>
<TI>The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/ schizoaffective disorder</TI>
<SO>8th Congress of the Association of European Psychiatrists, London, UK</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrigan E, Morrissey M, Ziprasidone Working Group</AU>
<TI>The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder</TI>
<SO>XXth Collegium Internationale Neuro-psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrigan EP, Morrissey M, Ziprasidone Working Group</AU>
<TI>The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia</TI>
<SO>149th American Psychiatric Association Meeting</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Full paper. Attrition 45%.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR</AU>
<TI>Ziprasidone 40 and 120mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a four-week placebo-controlled trial</TI>
<SO>Psychopharmacology</SO>
<YR>1998</YR>
<VL>140</VL>
<PG>173-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keck PE, Reeves KR, Harrigan EP, Laminarayanan M, Ziprasidone Study Group</AU>
<TI>Ziprasidone reduces overall psychopathology and symptoms of depression in the acute treatment of schizoaffective disorder</TI>
<SO>American Psychiatric Association, Washington DC</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>O'Connor R, Harrigan E, Heym J, Ko G, Chandler L</AU>
<TI>The efficacy and safety profile of a new antipsychotic, ziprasidone</TI>
<SO>8th European College of Neuropsychopharmacology Congress</SO>
<YR>1995</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT605"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Swift-1998" NAME="Swift 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Swift RH, Harrigan EP, van Kammen DP</AU>
<TI>A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol</TI>
<SO>151st American Psychiatric Association Meeting</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Allison-1998" NAME="Allison 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Mentore JL, Heo M, Weiden PJ, Cappelleri J, Chandler LP</AU>
<TI>Weight gain associated with conventional and newer antipsychotics: a meta-analysis</TI>
<SO>European Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>Supplement 4</NO>
<PG>302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bench-1993" NAME="Bench 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, Cuddigan M, Turton DJ, Osman S, Frackowiak RSJ</AU>
<TI>Dose dependent occupancy of contral dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>112</VL>
<PG>308-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT240"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brook-1997" NAME="Brook 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brook S, Swift R, Harrigan EP</AU>
<TI>The tolerability and efficacy of intramuscular ziprasidone</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>Supplement 2</NO>
<PG>215</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT611"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1999a" NAME="Daniel 1999a" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Daniel D, Stern R, Kramer T, Switch Study Group</AU>
<TI>Switching olanzapine to ziprasidone: clinical effects</TI>
<SO>World Congress of Psychiatry, Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1997" NAME="Davis 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;review&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis R, Markham A</AU>
<TI>Ziprasidone</TI>
<SO>CNS drugs</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>2</NO>
<PG>153-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT550"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunn-1996" NAME="Gunn 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Gunn KP, Harrigan EP, Heym J</AU>
<TI>The safety and tolerability of ziprasidone treatment</TI>
<SO>Critical issues in the treatment of schizophrenia</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>172-7</PG>
<ED>Brunello N, Racagni G, Langer SZ, Mendlewicz J</ED>
<PB>Karger</PB>
<CY>Basel</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gunn KP, Wright P</AU>
<TI>Ziprasidone - safety and efficacy</TI>
<SO>8th Biennial Winter Workshop on Schizophrenia, Switzerland</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT241 CSG1484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagger-1997" NAME="Hagger 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hagger C, Mitchell D, Wise AL, Schulz SC</AU>
<TI>Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: preliminary data</TI>
<SO>10th European College of Neuropsychopharmacology Congress</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT185"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell D, Hagger C, Wise AL, Schulz SC</AU>
<TI>Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: preliminary data</TI>
<SO>Schizophrenia Research (Special Issue)</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>116</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT181 CSG1706"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howard-1994" NAME="Howard 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Early review.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Howard HR, Prakash C, Seeger TF</AU>
<TI>Ziprasidone Hydrochloride</TI>
<SO>Drugs of the Future</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>6</NO>
<PG>560-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT528"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miceli-1998" NAME="Miceli 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miceli J, Preskorn S, Wilner K, Folger C, Tensfeldt T</AU>
<TI>Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: population pharmacokinetic modelling</TI>
<SO>European Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>4</NO>
<PG>304-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT613"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miceli-1999" NAME="Miceli 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Miceli J, Tensfeldt T, Folger C, Smolarek T, Muirhead G, Anziano R, Wilner K</AU>
<TI>Lack of drug interactions with ziprasidone: an overview</TI>
<SO>World Congress of Psychiatry, Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT631"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muirhead-1996" NAME="Muirhead 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Muirhead G, Holt P, Oliver S, Harness J, Anziano R</AU>
<TI>The effect of ziprasidone on steady-state pharmacokinetics of a combined oral contraceptive</TI>
<SO>8th Congress of the Association of European Psychiatrists, London, UK</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT256, CSG1546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Muirhead GJ, Holt PR, Oliver S, Harness J, Anziano RJ</AU>
<TI>The effect of ziprasidone on steady-state pharmacokinetics of a combined oral contraceptive</TI>
<SO>149th Annual Meeting of the American Psychiatric Association</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT246 CSG879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Muirhead GJ, Holt PR, Oliver S, Harness J, Anziano RJ</AU>
<TI>The effect of ziprasidone on steady-state pharmacokinetics of a combined oral contraceptive</TI>
<SO>XXth Collegium Internationale Neuro-psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT245 CSG915"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murasaki-1997" NAME="Murasaki 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Murasaki M</AU>
<TI>An open-label, Japanese, Phase II clinical trial of ziprasidone in the treatment of schizophrenia</TI>
<SO>10th European College of Neuropsychopharmocology Congress, Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT514"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reeves-1998a" NAME="Reeves 1998a" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reeves KR, Swift RH, Harrigan EP</AU>
<TI>A randomised, double-blind comparison of rapid-acting, intramuscular ziprasidone 2mg and 20mg in patients with psychosis and acute agitation</TI>
<SO>European Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>Supplement 4</NO>
<PG>303-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reeves-1998b" NAME="Reeves 1998b" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reeves KR, Swift RH, Harrigan EP</AU>
<TI>Rapid-acting, intramuscular ziprasidone 10mg and 20mg in patients with psychosis and acute agitation: results of two double-blind, randomised, fixed-dose studies</TI>
<SO>European Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>Supplement 4</NO>
<PG>304</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT615"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scahill-1998" NAME="Scahill 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;review&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scahill L, Lynch KA</AU>
<TI>Atypical neuroleptics in children and adolescents</TI>
<SO>Journal of Child and Adolescent Psychiatric Nursing</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>1</NO>
<PG>38-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seeger-1995" NAME="Seeger 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, Heym J</AU>
<TI>Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1995</YR>
<VL>275</VL>
<NO>1</NO>
<PG>101-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simansky-1999" NAME="Simansky 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Simansky KJ, Zorn SH, Schmidt AW, Lebel LA</AU>
<TI>Lack of weight gain and receptor binding with ziprasidone</TI>
<SO>World Congress of Psychiatry, Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT627"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Simansky KJ, Zorn SH, Schmidt AW, Lebel LA</AU>
<TI>The unique human receptor binding profile may be related to lack of weight gain with ziprasidone</TI>
<SO>American Psychiatric Association, Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT620"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1999" NAME="Simpson 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Simpson G, POtkin S, Switch Study Group</AU>
<TI>Switching from risperidone to ziprasidone: an interim analysis of a six-week study</TI>
<SO>American Psychiatric Association Meeting, Washington DC, USA</SO>
<YR>May 15-20, 1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT623"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Simpson G, Potkin S, Switch Study Group</AU>
<TI>Switching from risperidone to ziprasidone</TI>
<SO>World Congress of Psychiatry, Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT621"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tandon-1997" NAME="Tandon 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Harrigan E, Zorn SH</AU>
<TI>Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential</TI>
<SO>Journal of Serotonin Research</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>149-77</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="review"/>
<IDENTIFIER TYPE="OTHER" VALUE="NNR096"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tensfeldt-1998" NAME="Tensfeldt 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tensfeldt T, Miceli J, Kuye O, Reeves K, Swift R, Harrigan E</AU>
<TI>The population pharmacokinetics of intramuscular ziprasidone in healthy volunteers and schizophrenic patients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>Supplement 2</NO>
<PG>S239</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT618"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiden-1999" NAME="Weiden 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weiden P, Simpson G, Kramer T, Harvey P, Switch Study Group</AU>
<TI>Switching conventional antipsychotics to ziprasidone</TI>
<SO>World Congress of Psychiatry, Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Weiden P, Simpson G, Kramer T, Harvey P, Switch Study Group</AU>
<TI>Switching from conventional antipsychotics to ziprasidone: an interim analysis of a six-week study</TI>
<SO>American Psychiatric Association Meeting, Washington DC, USA</SO>
<YR>15-20 May, 1999</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilner-1996a" NAME="Wilner 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wilner K, Hansen R, Johnson A, Miceli J, Apseloff G, Gerber N</AU>
<TI>Single and multiple dose pharmacokinetics of ziprasidone in healthy males</TI>
<SO>8th Congress of the Association of European Psychiatrists, London, UK</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT255 CSG1542"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wilner KD, Hansen RA, JOhnson AC, Miceli JJ, Apseloff G, Gerber N</AU>
<TI>Single and multiple dose pharmacokinetics of ziprasidone in healthy males</TI>
<SO>149th Annual Meeting of the American Psychiatric Association</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT247 CSG858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Wilner KD, Hansen RA, Johnson AC, Miceli JJ, Apseloff G, Gerber N</AU>
<TI>Single and multiple dose pharmacokinetics of ziprasidone in healthy males</TI>
<SO>XXth Collegium Internationale Neuro-psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT242 CSG905"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilner-1996b" NAME="Wilner 1996b" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Wilner KD, Anziano RJ, Tensfeldt TG, Pelletier SN, Apseloff G, Gerber N</AU>
<TI>The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium</TI>
<SO>149th Annual Meeting of the American Psychiatric Association</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NNT248 CSG859"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-STUDY-115" NAME="STUDY 115" YEAR="1999">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-STUDY-301" NAME="STUDY 301" YEAR="1999">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-STUDY-302" NAME="STUDY 302" YEAR="1999">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-11 14:59:18 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-11 14:59:18 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-1999" NAME="Adams 1999" TYPE="UNPUBLISHED">
<AU>Adams CE, Gray R, Daniels J, Thornley B, Philpott H, Wahlbeck K</AU>
<TI>A survey of UK consultant psychiatrists first and second choice drug treatments for schizophrenia</TI>
<SO>Schizophrenia Trials Meeting, Stratford-upon-Avon, UK</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ZIP300800"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the assessment of negative symptoms (SANS)</SO>
<YR>1984</YR>
<PB>University of Iowa</PB>
<CY>Iowa City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1997" NAME="APA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>1-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomised controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-1997" NAME="Buckley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Buckley PF</AU>
<TI>New dimensions in the pharmacologic treatment of schizophrenia and related psychoses</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>37</VL>
<PG>363-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-1997" NAME="Casey 1997" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE</AU>
<TI>The relationship of pharmacology to side effects</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>10</NO>
<PG>55-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" MODIFIED="2008-11-11 14:55:26 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewer's Handbook 4.0 [updated July 1999]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2000</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-COSTART-1990" NAME="COSTART 1990" TYPE="BOOK">
<AU>US Food and Drug Administration</AU>
<SO>COSTART coding symbols for thesaurus of adverse reaction terms</SO>
<YR>1990</YR>
<EN>2nd</EN>
<PB>Food and Drug Administration</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CWG-1998" NAME="CWG 1998" TYPE="JOURNAL_ARTICLE">
<AU>Collaborative Working Group on Clinical Trial Evaluations</AU>
<TI>Adverse effects of the atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-1999" MODIFIED="2008-11-11 14:54:21 +0000" MODIFIED_BY="[Empty name]" NAME="Duggan 1999" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-11 14:54:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-11 14:54:07 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1976" NAME="Endicott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL, Fleiss JL, Cohen J</AU>
<TI>The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<NO>6</NO>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geddes-1999" NAME="Geddes 1999" TYPE="CONFERENCE_PROC">
<AU>Geddes J</AU>
<TI>Guidelines on for the care of those with schizophrenia</TI>
<SO>Schizophrenia Trials Meeting, Stratford-upon-Avon, UK</SO>
<YR>May 5-9th, 1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazer-1997" NAME="Glazer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Johnstone BM</AU>
<TI>Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>10</NO>
<PG>50-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2008-11-11 14:59:18 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy W</AU>
<TI>Clinical Global Impressions</TI>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PG>217-22</PG>
<PB>National Institute of Mental Health</PB>
<CY>Washington DC</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Publication No. 76-338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kane-1996" NAME="Kane 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Factors which can make patients difficult to treat</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<NO>31</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A, Opler LA</AU>
<TI>The Positive and Negative Syndrome Scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-1999" MODIFIED="2008-11-11 14:57:15 +0000" MODIFIED_BY="[Empty name]" NAME="Kennedy 1999" TYPE="COCHRANE_REVIEW">
<AU>Kennedy E, Song F, Hunter R, Clark A, Gilbody S</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-11 14:57:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-11 14:57:15 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1994" NAME="Kerwin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin RW</AU>
<TI>The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>164</VL>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1996" NAME="Kerwin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin R, Taylor D</AU>
<TI>New antipsychotics. A review of their current status and clinical potential</TI>
<SO>CNS Drugs</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>71-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connor-1995" NAME="O'Connor 1995" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor R, Harrigan E</AU>
<TI>The preclinical profile of the new antipsychotic ziprasidone</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1995</YR>
<VL>332</VL>
<PG>4-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstone-1995" NAME="Silverstone 1995" TYPE="BOOK">
<AU>Silverstone T, Turner P</AU>
<SO>Drug treatment in psychiatry</SO>
<YR>1995</YR>
<EN>5th</EN>
<PB>TJ Press</PB>
<CY>Cornwall</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>S11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-1998" MODIFIED="2008-11-11 14:56:22 +0000" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 1998" TYPE="COCHRANE_REVIEW">
<AU>Srisupanont M, Disayavanish C, Taimkaew K</AU>
<TI>Quetiapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-11 14:56:22 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-11 14:56:22 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000967.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-MacKenzie-1998" NAME="Wood MacKenzie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wood MacKenzie</AU>
<TI>Review of the Global Schizophrenia Market</TI>
<SO>PharmaForum</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Arato-1997">
<CHAR_METHODS>
<P>Allocation: random - using computer-generated pseudo-random code. Blinded code envelopes were used; investigators, patients and study staff were blind to treatment allocation.<BR/>Blinding: double - no further information<BR/>Duration: 1 year<BR/>Setting: Inpatients, 27 centres.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N=294.<BR/>Age: mean ~50 years.<BR/>Sex: 214 M, 80 F.<BR/>History: ill mean ~70 months, seriously impaired social and occupational functioning.<BR/>Excluded: acute exacerbation, severely ill (CGI&gt;5), PANSS &gt;4 for hostility or uncooperativeness, treatment-resistant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 40mg/day. N=76.<BR/>2. Ziprasidone: dose 80mg/day. N=72.<BR/>3. Ziprasidone: dose 160mg/day. N=71.<BR/>4. Placebo. N=75.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global impression (CGI-S, GAF)<BR/>Mental state: impending relapse.<BR/>Mental state (PANSS total, PANSS negative, BPRSd total, BPRSd core)<BR/>Side-effects (listed, SAS, BAS, AIMS)<BR/>Leaving study early.<BR/>Body weight.</P>
<P>Unable to use -<BR/>Side-effects: Use of additional medication (no data)<BR/>Laboratory results (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 303.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brook-1998">
<CHAR_METHODS>
<P>Allocation: random, no further information.<BR/>Blinding: single (outcomes rated blind but impossible to blind people giving the treatment, as I_M ziprasidone has a noticeably different viscosity from I-M haloperidol)).<BR/>Duration: 1 week (3 day IM phase, 4 days oral).<BR/>Setting: Inpatients, international multicentre trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: non-organic acute psychosis - schizophrenia (n=92), schizoaffective (n=8), delusional, bipolar, psychotic disorders (DSM-III-R).<BR/>N=132.<BR/>Age: range 19-66 years.<BR/>Sex: 123 M, 9 F.<BR/>History: currently acute.<BR/>Excluded: epilepsy, febrile convulsions, mental retardation, organic mental syndromes, allergy to neuroleptics, substance abuse, laboratory test abnormality.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: 10mg IM, then 5-20mg every 4-6h (3 days) mean ~12mg/day, then 80-200mg/day oral (4 days max.), mean ~91mg/day. N=90.<BR/>2. Haloperidol: 2.5-10mg IM, then 2.5-10mg every 4-6h (3 days) mean ~5mg/day, then 10-80mg/day oral (4 days max.), mean ~14 mg/day. N=42.</P>
<P>Anticholinergics and benzodiazepines as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (BPRS total).<BR/>Leaving study early.<BR/>Side effects.</P>
<P>Unable to use - <BR/>Global state: CGI-I, CGI-S (no SD).<BR/>Behaviour: NOSIE (no data).<BR/>Side effects: AIMS (no data), Simpson-Angus scale, Barnes Akathisia scale (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 306. <BR/>Publication pending.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Daniel-1999">
<CHAR_METHODS>
<P>Allocation: random - computer-generated pseudo-random code. Blinded code envelopes were used; investigators, patients and study staff were blind to treatment allocation.<BR/>Blinding: Double, no further information.<BR/>Duration: 6 weeks, following 3-7 day washout phase.<BR/>Setting: Multicentre, inpatients for first two weeks, unclear thereafter.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, schizoaffective disorder (DSM-III-R).<BR/>N=302.<BR/>Age: range 18-67 years.<BR/>Sex: 215 M, 87 F.<BR/>History: acute exacerbation, PANSS total &gt;59, &gt;4 on &gt;1 PANSS core items, CGI &gt;2 in previous 24h.<BR/>Excluded: treatment resistant, substance abuse, long term hospitalised, suicidal/ homicidal, those on depot medication in last 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 80mg/day. N=106.<BR/>2. Ziprasidone: dose 80mg/day (2 days), then 160mg/day. N=104.<BR/>3. Placebo. N=92.</P>
<P>Lorazepam, benztropine and B-adrenoceptor antagonists (akathisia) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global impression (CGI-I, CGI-S).<BR/>Mental state (PANSS negative, PANSS total, BPRSd total, BPRSd core).<BR/>Leaving the study early.<BR/>Side events (COSTART).<BR/>Laboratory test abnormalities.<BR/>Side effects (SAS, BAS, AIMS).</P>
<P>Unable to use -<BR/>Mental state: MADRS (skewed data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 114.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goff-1998">
<CHAR_METHODS>
<P>Allocation: random - computer-generated pseudo-random code. Blinded code envelopes were used; investigators, patients and study staff were blind to treatment allocation.<BR/>Blinding: double - no further information.<BR/>Duration: 4 weeks (preceded by 4-7 day washout).<BR/>Setting: 6 centres in Boston, USA: 2 Veterans hospitals, 3 state psychiatric hospitals and one community mental health centre. Impatients for first 14 days, unclear status thereafter.<BR/>Power calculation: undertaken, to demonstrate a 25% difference between groups on BPRS, with 20 patients per group at 80%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (n=63), schizoaffective disorder (n=27) (DSM-III-R).<BR/>N=90.<BR/>Age: range 21-61 years, mean ~40.<BR/>Sex: 84 M, 6 F.<BR/>History: acute exacerbation in last 2 weeks or 3 months current hospitalisation, BPRS total &gt;24, BPRS core &gt;3 on 1+ items, in hospital for first 14 days, unclear status thereafter.<BR/>Exclude: treatment-resistant, comorbid axis I psychiatric disorders, medical or neurologic disorders, depot medication in last 2 months, recent 'illicit' substance use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 4mg/day. N=19.<BR/>2. Ziprasidone: dose 10mg/day. N=17.<BR/>3. Ziprasidone: dose 40mg/day. N=17.<BR/>4. Ziprasidone: dose 160mg/day. N=20.<BR/>5. Haloperidol: dose 15mg/day. N=17.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global impression: CGI-S (no SD), CGI-I (no data), response (&gt;50% attrition).<BR/>Mental state: BPRS total, BPRS core (no SD), response (&gt;50% attrition), SANS (no data).<BR/>Side effects: SAS, BAS, AIMS (no SD), any adverse event, use of additional medication (&gt;50% attrition).<BR/>Laboratory results: serum prolactin (&gt;50% attrition).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 101.</P>
<P>All outcomes except 'leaving the study early' excluded - attrition 51% (46/ 90).</P>
<P>ITT analysis - last observation carried forward or observed case analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hirsch-1999">
<CHAR_METHODS>
<P>Allocation: random, using computer-generated pseudo-random code. Blinded code envelopse were used; investigators, patients and study staff were blind to treatment allocation.<BR/>Blinding: double, no further information.<BR/>Duration: 28 weeks.<BR/>Setting: Multicentre trial in stable outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N=301.<BR/>Age: range 18-64 years.<BR/>Sex: 197 M, 104 F.<BR/>History: without acute exacerbation, &gt;9 PANSS negative subscale, &gt;30 on GAF, stable outpatients.<BR/>Excluded: inpatients in last 12 weeks, &gt;4 PANSS hostility or uncooperativeness, &gt;5 CGI-I, ECG or laboratory abnormality, substance abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: titrated dose 80-160mg/day, flexible, mode 80mg/day. N=148.<BR/>2. Haloperidol: titrated dose 5-15mg/day, flexible, mode 5mg/day. N=153.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global impression: CGI-S<BR/>Mental state: response (PANSS negative subscale score).<BR/>Mental state (PANSS total, PANSS negative, BPRSd core, MADRS)<BR/>Leaving the study early.<BR/>Side effects: COSTART<BR/>Side effects: SAS, BAS, AIMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 304.<BR/>Poster only. </P>
<P>Attrition &gt;25% (data derived from efficacy tables).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Keck-1998">
<CHAR_METHODS>
<P>Allocation: random - computer-generated pseudo-random code. Blinded code envelopes were used; investigators, patients and study staff were blind to treatment allocation.<BR/>Blinding: double - no further information.<BR/>Duration: 4 weeks (preceded by 4-7 day washout).<BR/>Setting: multicentre, unclear whether inpatients throughout.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, schizoaffective disorder (DSM-III-R).<BR/>N=139.<BR/>Age: range 19-76 years.<BR/>Sex: 110 M, 29 F.<BR/>History: acute exacerbation, duration ill &gt;1 year (mean ~16 years), BPRS total &gt;37, BPRS core &gt;3 on &gt;2 items.<BR/>Exclude: treatment-resistant, in residential care centre, substance abuse in last 6 months, residual schizophrenia, mental retardation, organic mental syndrome, brief reactive psychosis, depot medication in last 2 months, abnormal ECG, laboratory tests, abnormal weight.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 40mg/day. N=44.<BR/>2. Ziprasidone: dose 120mg/day. N=47.<BR/>3. Placebo. N=48.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global impression: CGI-S, response.<BR/>Mental state: BPRS total, BPRS core item, SANS, response.<BR/>Leaving the study early.<BR/>Side effects: COSTART.<BR/>Laboratory results.<BR/>Side effects (SAS, BAS, AIMS).</P>
<P>Unable to use - <BR/>Mental state: BPRS depression cluster, BPRS anergia factor (skewed data).<BR/>Side effects: cardiac data (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 106.</P>
<P>ITT analysis - last observation carried forward - included all patients with baseline + 1 assessment. Seven participants did not meet this criteria.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Swift-1998">
<CHAR_METHODS>
<P>Allocation: random, no further information.<BR/>Blinding: single (outcomes rated blind, but impossible to blind people giving the treatment, as I_M ziprasidone has a noticeably different viscosity from I-M haloperidol).<BR/>Duration: 1 week (3 days IM, 4 days oral medication).<BR/>Setting: Inpatients, multicentre trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: acutely psychotic - schizophrenia (n=207), schizophreniform (n=1), schizoaffective (n=63), delusional disorder (n=2), bipolar with psychotic features (n=24), psychotic other (n=9) (DSM-III-R).<BR/>N=306.<BR/>Age: range 19-72 years.<BR/>Sex: 271 M, 35 F.<BR/>History: inpatients.<BR/>Exclude: substance abuse, received ziprasidone or clozapine in last 12 weeks, over or under weight.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 80mg/day IM (3 days), then 40-200mg/day oral, flexible (4 days max.). N=69.<BR/>2. Ziprasidone: dose 160mg/day IM (3 days), then 40-200mg/day oral, flexible (4 days max.). N=71.<BR/>3. Ziprasidone: dose 320mg/day IM (3 days), then 40-200mg/day oral, flexible (4 days max.). N=66.<BR/>4. Haloperidol: dose 10-40 mg IM X 2-4/day (3 days), then flexible oral dose (4 days max.). N=100.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving study early.<BR/>Side effects.</P>
<P>Unable to use -<BR/>Global assessment: CGI-I, CGI-S (no SD).<BR/>Mental state: BPRS total, BPRS agitation (no SD), BPRS core (no data).<BR/>Side effects: AIMS, Simpson Angus Scale, Barnes Akathisia Scale, use of antiparkinson medication (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>STUDY 121<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DSM-III-R - Diagnostic and Statistical Manual, version 3, revised.<BR/>IM - intramuscular injection<BR/>AIMS - Abnormal Involuntary Movement Scale - no data).<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>CGI - Clincal Global Impression<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Allison-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bench-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brook-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daniel-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gunn-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, review of pooled data from phase II studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hagger-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>STUDY 117 - Conference abstract only. All outcomes unusable due to overall attrition = 55% (6/ 11). N for treatment groups not given.</P>
<P>Allocation: random - no further information.<BR/>Blinding: unclear.<BR/>Duration: 52 weeks - preceded by washout of 3-14 days.<BR/>Setting: outpatients.</P>
<P>Diagnosis: schizophrenia, schizoaffective disorder (DSM-IV).<BR/>N=11.<BR/>Age: range 22-47 years.<BR/>Sex: 7 M, 4 F.<BR/>History: stable outpatients.<BR/>Exclude: if hospitalised in last 12 weeks.</P>
<P>1. Ziprasidone: dose 80-160mg/day. N=not stated.<BR/>2. Risperidone: dose 6-10mg/day. N=not stated.</P>
<P>Mental state, cognitive tests (NAART-R, WAIS-R, verbal fluency, FAS, attention, PASAT, Trailmaking test part A; memory: BVRT, CVLT, executive functioning, Trailmaking test part B, WCST) - unusable due to high attrition. Leaving the study early (no group data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Howard-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: part randomised.<BR/>Participants: animals and healthy volunteers, not those with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miceli-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miceli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muirhead-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random.<BR/>Participants: healthy volunteers, not those with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murasaki-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reeves-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reeves-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scahill-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seeger-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simansky-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, in vitro data only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tandon-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tensfeldt-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, review, including studies on healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiden-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilner-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: healthy volunteers, not those with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilner-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: healthy volunteers, not those with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-STUDY-115">
<CHAR_STUDY_NAME>
<P>Study 115</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Diagnosis: not stated. <BR/>N=419.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 40mg/day.<BR/>2. Ziprasidone: dose 120mg/day.<BR/>3. Ziprasidone: dose 200mg/day.<BR/>4. Placebo.<BR/>5. Haloperidol: dose 15mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not stated.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Unknown.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Pfizer - data on file.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Unpublished data.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-STUDY-301">
<CHAR_STUDY_NAME>
<P>Study 301</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Diagnosis: not stated.<BR/>N=597.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose 40mg/day.<BR/>2. Ziprasidone: dose 120mg/day.<BR/>3. Ziprasidone: dose 200mg/day.<BR/>4. Haloperidol: dose 10mg/day.<BR/>5. Haloperidol: dose 20mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not stated.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Unknown.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Pfizer - data on file.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>12 weeks duration.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-STUDY-302">
<CHAR_STUDY_NAME>
<P>Study 302</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Diagnosis: not stated.<BR/>N=296.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Ziprasidone: dose - flexible.<BR/>2. Risperidone: dose - flexible.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not stated.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Unknown.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Pfizer - data on file.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>8 weeks duration. Possibly Follow-up to Hagger 1997</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Arato-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brook-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Daniel-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goff-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Keck-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Swift-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>ZIPRASIDONE versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="0.05690148486701433" CI_END="0.9577999762880324" CI_START="0.7583880743129476" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8522816902844198" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.0187251780451096" LOG_CI_START="-0.1201085049168277" LOG_EFFECT_SIZE="-0.06941684148096867" METHOD="MH" NO="1" P_CHI2="0.8114620479640485" P_Q="0.0" P_Z="0.007275532861605662" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="2.683962213932406">
<NAME>Global impression: 1. No response (CGI-I score &gt;2 at last observation)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9909376955776883" CI_START="0.7188122697828949" EFFECT_SIZE="0.8439775910364146" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="68" LOG_CI_END="-0.003953650577721791" LOG_CI_START="-0.1433845182999503" LOG_EFFECT_SIZE="-0.07366908443883606" ORDER="281" O_E="0.0" SE="0.08190238189396357" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.006708000159904651" WEIGHT="63.23084744855637"/>
<DICH_DATA CI_END="1.0146580241441507" CI_START="0.740081582464158" EFFECT_SIZE="0.8665620094191523" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="42" LOG_CI_END="0.006319694217417335" LOG_CI_START="-0.1307204034297204" LOG_EFFECT_SIZE="-0.062200354606151524" ORDER="282" O_E="0.0" SE="0.08049803171735252" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.006479933110367892" WEIGHT="36.76915255144363"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4432888899588465" CI_END="-0.010314887762233327" CI_START="-0.598498087616699" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30440648768946615" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.5055393295908223" P_Q="0.5055393295908223" P_Z="0.04248811993318628" Q="0.4432888899588465" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="94" UNITS="" WEIGHT="200.0" Z="2.028707221421191">
<NAME>Global impression: 2. Average change (CGI-S change score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6354220242044555E-32" CI_END="0.2253862114149793" CI_START="-0.6253862114149794" DF="0.0" EFFECT_SIZE="-0.20000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.0" P_Z="0.35679018421390174" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0" Z="0.9214985967789352">
<NAME>Ziprasidone 40mg</NAME>
<CONT_DATA CI_END="0.22538621141497933" CI_START="-0.6253862114149793" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.2" ORDER="283" SD_1="1.2" SD_2="0.8" SE="0.2170377694541183" STUDY_ID="STD-Keck-1998" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.144780657604048E-32" CI_END="0.0070369869727124335" CI_START="-0.8070369869727123" DF="0.0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.0" P_Z="0.05409444868859792" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0" Z="1.9260794937747998">
<NAME>Ziprasidone 120mg</NAME>
<CONT_DATA CI_END="0.007036986972712378" CI_START="-0.8070369869727123" EFFECT_SIZE="-0.39999999999999997" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.2" ORDER="284" SD_1="1.1" SD_2="0.8" SE="0.20767574821954288" STUDY_ID="STD-Keck-1998" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.838378355116996" CI_END="-0.3930135270393538" CI_START="-0.7193473179583647" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5561804224988592" ESTIMABLE="YES" I2="31.48782492840268" I2_Q="31.48782492840268" ID="CMP-001.03" NO="3" P_CHI2="0.21154786816297066" P_Q="0.21154786816297066" P_Z="2.3755985773323005E-11" Q="5.838378355116996" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="425" TOTAL_2="409" UNITS="" WEIGHT="100.0" Z="6.680850266435162">
<NAME>Global impression: 3. Endpoint score (CGI-S)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.18144400241841901" CI_START="-0.9785559975815812" DF="0.0" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.004341170958081055" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="16.760439510160037" Z="2.8522443971014195">
<NAME>Ziprasidone 40mg - long term</NAME>
<CONT_DATA CI_END="-0.18144400241841901" CI_START="-0.9785559975815812" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" MEAN_1="4.39" MEAN_2="4.97" ORDER="285" SD_1="1.27" SD_2="1.22" SE="0.20334863330415248" STUDY_ID="STD-Arato-1997" TOTAL_1="75" TOTAL_2="75" WEIGHT="16.760439510160037"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04391902962100369" CI_START="-0.6039190296210042" DF="0.0" EFFECT_SIZE="-0.28000000000000025" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="1.0" P_Z="0.09022359287434162" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="92" WEIGHT="25.37413086201211" Z="1.6942194359908962">
<NAME>Ziprasidone 80mg - short term</NAME>
<CONT_DATA CI_END="0.04391902962100369" CI_START="-0.6039190296210042" EFFECT_SIZE="-0.28000000000000025" ESTIMABLE="YES" MEAN_1="4.27" MEAN_2="4.55" ORDER="1" SD_1="1.16" SD_2="1.15" SE="0.16526784786661178" STUDY_ID="STD-Daniel-1999" TOTAL_1="104" TOTAL_2="92" WEIGHT="25.37413086201211"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.6624609343083488E-31" CI_END="-0.4082872819201347" CI_START="-1.2517127180798657" DF="0.0" EFFECT_SIZE="-0.8300000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-001.03.03" NO="3" P_CHI2="0.0" P_Z="1.1453790730805309E-4" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="14.970306885606709" Z="3.857531531359132">
<NAME>Ziprasidone 80mg - long term</NAME>
<CONT_DATA CI_END="-0.4082872819201346" CI_START="-1.2517127180798655" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="4.14" MEAN_2="4.97" ORDER="287" SD_1="1.38" SD_2="1.22" SE="0.21516350372062015" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="75" WEIGHT="14.970306885606709"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.19834885233954402" CI_START="-0.8216511476604555" DF="0.0" EFFECT_SIZE="-0.5099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.04" NO="4" P_CHI2="1.0" P_Z="0.0013395295808117282" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="92" WEIGHT="27.41111109034747" Z="3.207373499565843">
<NAME>Ziprasidone 160mg - short term</NAME>
<CONT_DATA CI_END="-0.19834885233954397" CI_START="-0.8216511476604555" EFFECT_SIZE="-0.5099999999999998" ESTIMABLE="YES" MEAN_1="4.04" MEAN_2="4.55" ORDER="288" SD_1="1.06" SD_2="1.15" SE="0.15900860940237693" STUDY_ID="STD-Daniel-1999" TOTAL_1="103" TOTAL_2="92" WEIGHT="27.41111109034747"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.38534175460742975" CI_START="-1.2146582453925698" DF="0.0" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.05" NO="5" P_CHI2="1.0" P_Z="1.5597531204238E-4" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="15.484011651873669" Z="3.781357792964168">
<NAME>Ziprasidone 160mg - long term</NAME>
<CONT_DATA CI_END="-0.38534175460742975" CI_START="-1.2146582453925698" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.17" MEAN_2="4.97" ORDER="289" SD_1="1.33" SD_2="1.22" SE="0.2115642168240546" STUDY_ID="STD-Arato-1997" TOTAL_1="71" TOTAL_2="75" WEIGHT="15.484011651873669"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.25613597867267923" CI_END="-5.142760611653696" CI_START="-11.67065267717409" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.406706644413893" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.8797935660223734" P_Q="0.8797935660223734" P_Z="4.461423915518826E-7" Q="0.25613597867267923" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="222" UNITS="" WEIGHT="100.0" Z="5.048135626712845">
<NAME>Global impression: 4. Endpoint score (GAF)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.7945716188526184" CI_START="-12.885428381147374" DF="0.0" EFFECT_SIZE="-7.339999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.00948020992767818" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="74" WEIGHT="34.643019410880534" Z="2.594233422152217">
<NAME>Ziprasidone 40mg - long term</NAME>
<CONT_DATA CI_END="-1.7945716188526184" CI_START="-12.885428381147374" EFFECT_SIZE="-7.339999999999996" ESTIMABLE="YES" MEAN_1="-45.15" MEAN_2="-37.81" ORDER="290" SD_1="18.9" SD_2="15.49" SE="2.829352184473291" STUDY_ID="STD-Arato-1997" TOTAL_1="75" TOTAL_2="74" WEIGHT="34.643019410880534"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.880486252984765" CI_START="-14.259513747015236" DF="0.0" EFFECT_SIZE="-8.57" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.003154630267042842" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="74" WEIGHT="32.910587605449685" Z="2.9522542864616597">
<NAME>Ziprasidone 80mg - long term</NAME>
<CONT_DATA CI_END="-2.880486252984765" CI_START="-14.259513747015236" EFFECT_SIZE="-8.57" ESTIMABLE="YES" MEAN_1="-46.38" MEAN_2="-37.81" ORDER="291" SD_1="19.32" SD_2="15.49" SE="2.902866477084984" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="74" WEIGHT="32.910587605449685"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.649932243899439" CI_START="-15.110067756100552" DF="0.0" EFFECT_SIZE="-9.379999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="0.0013346658148421947" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="74" WEIGHT="32.44639298366979" Z="3.208419683242411">
<NAME>Ziprasidone 160mg - long term</NAME>
<CONT_DATA CI_END="-3.649932243899439" CI_START="-15.110067756100552" EFFECT_SIZE="-9.379999999999995" ESTIMABLE="YES" MEAN_1="-47.19" MEAN_2="-37.81" ORDER="292" SD_1="19.27" SD_2="15.49" SE="2.9235576782525596" STUDY_ID="STD-Arato-1997" TOTAL_1="70" TOTAL_2="74" WEIGHT="32.44639298366979"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.14018836462956935" CI_END="0.9356217128786568" CI_START="0.7444262649044868" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8345665803767826" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="112" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.028899708117728486" LOG_CI_START="-0.12817831245978498" LOG_EFFECT_SIZE="-0.07853901028875673" METHOD="MH" NO="5" P_CHI2="0.7080939394489556" P_Q="0.0" P_Z="0.0019284000896441775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="140" WEIGHT="99.99999999999999" Z="3.1010434235561575">
<NAME>Mental state: 1. No response (30% decrease in BPRS total / PANSS total)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9640024558536995" CI_START="0.7448458628265167" EFFECT_SIZE="0.8473684210526315" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="76" LOG_CI_END="-0.01592185970468844" LOG_CI_START="-0.12793359013727013" LOG_EFFECT_SIZE="-0.07192772492097926" ORDER="293" O_E="0.0" SE="0.06579624492310646" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.004329145845981413" WEIGHT="69.15785063370691"/>
<DICH_DATA CI_END="1.0173445111941322" CI_START="0.6383399441162416" EFFECT_SIZE="0.8058608058608059" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="36" LOG_CI_END="0.0074680463095062755" LOG_CI_START="-0.19494797874660585" LOG_EFFECT_SIZE="-0.09373996621854978" ORDER="294" O_E="0.0" SE="0.11890017509344397" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.014137251637251633" WEIGHT="30.842149366293075"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8702314640405928" CI_START="0.5813535639713154" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7112750263435195" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.06036521843220608" LOG_CI_START="-0.23555966076032947" LOG_EFFECT_SIZE="-0.1479624395962678" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="9.308975517500175E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="219" TOTAL_2="75" WEIGHT="99.99999999999999" Z="3.3106193189647217">
<NAME>Mental state: 2. Impending relapse (CGI-I score of &gt;5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8702314640405928" CI_START="0.5813535639713154" EFFECT_SIZE="0.7112750263435195" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="52" LOG_CI_END="-0.06036521843220608" LOG_CI_START="-0.23555966076032947" LOG_EFFECT_SIZE="-0.1479624395962678" ORDER="295" O_E="0.0" SE="0.10291008265001567" STUDY_ID="STD-Arato-1997" TOTAL_1="219" TOTAL_2="75" VAR="0.010590485111033056" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11788479803674605" CI_END="0.9825757268592631" CI_START="0.8525052335409382" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9152327296910951" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.007633968698335426" LOG_CI_START="-0.06930294618769506" LOG_EFFECT_SIZE="-0.038468457443015226" METHOD="MH" NO="7" P_CHI2="0.7313400698164614" P_Q="0.0" P_Z="0.0144767939246339" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="2.4452097050621804">
<NAME>Mental state: 3. Needing to use additional sedation (lorazepam)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9861123511761855" CI_START="0.8344458344329014" EFFECT_SIZE="0.9071148459383753" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="85" LOG_CI_END="-0.006073601573858157" LOG_CI_START="-0.07860184900315569" LOG_EFFECT_SIZE="-0.042337725288506926" ORDER="296" O_E="0.0" SE="0.042603451560584364" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.0018150540848750583" WEIGHT="67.737755796265"/>
<DICH_DATA CI_END="1.0646872762351973" CI_START="0.816334027185971" EFFECT_SIZE="0.9322770253002811" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="43" LOG_CI_END="0.027222063972522758" LOG_CI_START="-0.08813210046112585" LOG_EFFECT_SIZE="-0.030455018244301555" ORDER="297" O_E="0.0" SE="0.06775960720064833" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.0045913643679861525" WEIGHT="32.26224420373499"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.6062280721704565" CI_END="0.19851075854053502" CI_START="-7.378241118389519" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.589865179924492" ESTIMABLE="YES" I2="37.74234074687011" I2_Q="37.74234074687011" ID="CMP-001.08" NO="8" P_CHI2="0.20502288373741595" P_Q="0.20502288373741595" P_Z="0.06327389582644351" Q="1.6062280721704565" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="94" UNITS="" WEIGHT="200.0" Z="1.8572619445094598">
<NAME>Mental state: 4a. Average change in mental state (BPRS total change score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.301699755607812" CI_START="-6.501699755607813" DF="0.0" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.6898001527554606" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0" Z="0.3991262899711957">
<NAME>Ziprasidone 40mg</NAME>
<CONT_DATA CI_END="4.301699755607811" CI_START="-6.501699755607812" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-4.1" ORDER="298" SD_1="13.8" SD_2="12.2" SE="2.7560199055777197" STUDY_ID="STD-Keck-1998" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6854904267481956" CI_START="-11.314509573251804" DF="0.0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="1.0" P_Z="0.026913551228160842" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0" Z="2.212769352496402">
<NAME>Ziprasidone 120mg</NAME>
<CONT_DATA CI_END="-0.6854904267481956" CI_START="-11.314509573251804" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-10.1" MEAN_2="-4.1" ORDER="299" SD_1="13.1" SD_2="12.2" SE="2.7115343012279705" STUDY_ID="STD-Keck-1998" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2727536052212878" CI_END="0.26347893987827775" CI_START="-2.3422158450479973" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0393684525848599" ESTIMABLE="YES" I2="21.430197023395223" I2_Q="21.430197023395223" ID="CMP-001.09" NO="9" P_CHI2="0.2592508423620057" P_Q="0.2592508423620057" P_Z="0.11791287845748226" Q="1.2727536052212878" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="94" UNITS="" WEIGHT="200.0" Z="1.563594282429429">
<NAME>Mental state: 4b. Average change in mental state (BPRS core item change score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5295825551100952" CI_START="-2.1295825551100958" DF="0.0" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.7479232855281739" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0" Z="0.32137888160320505">
<NAME>Ziprasidone 40mg</NAME>
<CONT_DATA CI_END="1.5295825551100952" CI_START="-2.1295825551100958" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-2.3" ORDER="300" SD_1="4.7" SD_2="4.1" SE="0.9334776401717629" STUDY_ID="STD-Keck-1998" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.055704067043575556" CI_START="-3.655704067043575" DF="0.0" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="1.0" P_Z="0.05728495177523145" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0" Z="1.9011302690049312">
<NAME>Ziprasidone 120mg</NAME>
<CONT_DATA CI_END="0.055704067043575556" CI_START="-3.655704067043575" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-2.3" ORDER="301" SD_1="4.7" SD_2="4.1" SE="0.9468051870754423" STUDY_ID="STD-Keck-1998" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.751831281627942" CI_END="-5.3447887843920565" CI_START="-9.796769012255718" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.570778898323887" ESTIMABLE="YES" I2="30.456930946905683" I2_Q="30.456930946905683" ID="CMP-001.10" NO="10" P_CHI2="0.21846414211872422" P_Q="0.21846414211872422" P_Z="2.6286614069623308E-11" Q="5.751831281627942" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="425" TOTAL_2="407" UNITS="" WEIGHT="100.0" Z="6.666001741319984">
<NAME>Mental state: 4c. Average mental state (BPRS total endpoint score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.868740308680989" CI_START="-14.311259691319004" DF="0.0" EFFECT_SIZE="-9.089999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="1.0" P_Z="6.443672593488025E-4" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="18.17589786679558" Z="3.4122172948207345">
<NAME>Ziprasidone 40mg - long term</NAME>
<CONT_DATA CI_END="-3.868740308680989" CI_START="-14.311259691319004" EFFECT_SIZE="-9.089999999999996" ESTIMABLE="YES" MEAN_1="48.52" MEAN_2="57.61" ORDER="302" SD_1="15.98" SD_2="16.64" SE="2.663956956609222" STUDY_ID="STD-Arato-1997" TOTAL_1="75" TOTAL_2="75" WEIGHT="18.17589786679558"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.798963151870435" CI_START="-7.838963151870441" DF="0.0" EFFECT_SIZE="-3.020000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="1.0" P_Z="0.21933760293990745" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="91" WEIGHT="21.337289587434096" Z="1.2282914491706638">
<NAME>Ziprasidone 80mg - short term</NAME>
<CONT_DATA CI_END="1.798963151870435" CI_START="-7.838963151870441" EFFECT_SIZE="-3.020000000000003" ESTIMABLE="YES" MEAN_1="48.73" MEAN_2="51.75" ORDER="303" SD_1="17.66" SD_2="16.65" SE="2.458699848508342" STUDY_ID="STD-Daniel-1999" TOTAL_1="104" TOTAL_2="91" WEIGHT="21.337289587434096"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.9303004296105417" CI_START="-14.34969957038946" DF="0.0" EFFECT_SIZE="-8.64" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" NO="3" P_CHI2="1.0" P_Z="0.003018517340331552" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="15.199172628450414" Z="2.9658458589040952">
<NAME>Ziprasidone 80mg - long term</NAME>
<CONT_DATA CI_END="-2.9303004296105417" CI_START="-14.34969957038946" EFFECT_SIZE="-8.64" ESTIMABLE="YES" MEAN_1="48.97" MEAN_2="57.61" ORDER="304" SD_1="18.58" SD_2="16.64" SE="2.9131655558096172" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="75" WEIGHT="15.199172628450414"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.821707596032172" CI_START="-11.398292403967826" DF="0.0" EFFECT_SIZE="-7.109999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.04" NO="4" P_CHI2="1.0" P_Z="0.0011555711624020393" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="91" WEIGHT="26.944968544248177" Z="3.249625402686121">
<NAME>Ziprasidone 160mg - short term</NAME>
<CONT_DATA CI_END="-2.821707596032172" CI_START="-11.398292403967826" EFFECT_SIZE="-7.109999999999999" ESTIMABLE="YES" MEAN_1="44.64" MEAN_2="51.75" ORDER="305" SD_1="13.39" SD_2="16.65" SE="2.1879444917321598" STUDY_ID="STD-Daniel-1999" TOTAL_1="103" TOTAL_2="91" WEIGHT="26.944968544248177"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.952530630594581" CI_START="-16.347469369405417" DF="0.0" EFFECT_SIZE="-11.149999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.05" NO="5" P_CHI2="1.0" P_Z="2.6147338857049312E-5" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="18.342671373071738" Z="4.2046613215772775">
<NAME>Ziprasidone 160mg - long term</NAME>
<CONT_DATA CI_END="-5.952530630594581" CI_START="-16.347469369405417" EFFECT_SIZE="-11.149999999999999" ESTIMABLE="YES" MEAN_1="46.46" MEAN_2="57.61" ORDER="306" SD_1="15.4" SD_2="16.64" SE="2.651818814224339" STUDY_ID="STD-Arato-1997" TOTAL_1="71" TOTAL_2="75" WEIGHT="18.342671373071738"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.511775198173077" CI_END="-1.173898169037022" CI_START="-2.6030425131894255" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8884703411132238" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.6425286075124071" P_Q="0.6425286075124071" P_Z="2.2213572228429612E-7" Q="2.511775198173077" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="425" TOTAL_2="407" UNITS="" WEIGHT="100.0" Z="5.1797900885220605">
<NAME>Mental state: 4d. Average mental state (BPRS core endpoint score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.23527354760388475" CI_START="-3.4647264523961145" DF="0.0" EFFECT_SIZE="-1.8499999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="1.0" P_Z="0.024733466181332132" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="19.58367885292531" Z="2.245540330387557">
<NAME>Ziprasidone 40mg - long term</NAME>
<CONT_DATA CI_END="-0.23527354760388475" CI_START="-3.4647264523961145" EFFECT_SIZE="-1.8499999999999996" ESTIMABLE="YES" MEAN_1="12.44" MEAN_2="14.29" ORDER="307" SD_1="5.07" SD_2="5.02" SE="0.8238551652647044" STUDY_ID="STD-Arato-1997" TOTAL_1="75" TOTAL_2="75" WEIGHT="19.58367885292531"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.929940021083688E-32" CI_END="0.7063413560762549" CI_START="-2.4263413560762537" DF="0.0" EFFECT_SIZE="-0.8599999999999993" ESTIMABLE="YES" I2="100.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.0" P_Z="0.2818742460610316" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="91" WEIGHT="20.81226605153218" Z="1.076118574131798">
<NAME>Ziprasidone 80mg - short term</NAME>
<CONT_DATA CI_END="0.7063413560762548" CI_START="-2.4263413560762537" EFFECT_SIZE="-0.8599999999999994" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="14.36" ORDER="308" SD_1="5.61" SD_2="5.53" SE="0.7991684380077159" STUDY_ID="STD-Daniel-1999" TOTAL_1="104" TOTAL_2="91" WEIGHT="20.81226605153218"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3370566987603436" CI_START="-3.7629433012396545" DF="0.0" EFFECT_SIZE="-2.049999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.03" NO="3" P_CHI2="1.0" P_Z="0.018995102779416254" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="17.402282823750404" Z="2.3456270650635895">
<NAME>Ziprasidone 80mg - long term</NAME>
<CONT_DATA CI_END="-0.3370566987603436" CI_START="-3.7629433012396545" EFFECT_SIZE="-2.049999999999999" ESTIMABLE="YES" MEAN_1="12.24" MEAN_2="14.29" ORDER="309" SD_1="5.55" SD_2="5.02" SE="0.8739667232414133" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="75" WEIGHT="17.402282823750404"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6701128828690297" CI_START="-3.6298871171309672" DF="0.0" EFFECT_SIZE="-2.1499999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.04" NO="4" P_CHI2="1.0" P_Z="0.004406933299541889" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="91" WEIGHT="23.31497850803849" Z="2.847462159769707">
<NAME>Ziprasidone 160mg - short term</NAME>
<CONT_DATA CI_END="-0.6701128828690297" CI_START="-3.6298871171309672" EFFECT_SIZE="-2.1499999999999986" ESTIMABLE="YES" MEAN_1="12.21" MEAN_2="14.36" ORDER="310" SD_1="4.91" SD_2="5.53" SE="0.7550583218896518" STUDY_ID="STD-Daniel-1999" TOTAL_1="103" TOTAL_2="91" WEIGHT="23.31497850803849"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9457532949117939" CI_START="-4.234246705088205" DF="0.0" EFFECT_SIZE="-2.59" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.05" NO="5" P_CHI2="1.0" P_Z="0.002019737749418278" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="18.886793763753605" Z="3.08731451566839">
<NAME>Ziprasidone 160mg - long term</NAME>
<CONT_DATA CI_END="-0.9457532949117939" CI_START="-4.234246705088205" EFFECT_SIZE="-2.59" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="14.29" ORDER="311" SD_1="5.11" SD_2="5.02" SE="0.8389167954400254" STUDY_ID="STD-Arato-1997" TOTAL_1="71" TOTAL_2="75" WEIGHT="18.886793763753605"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.1522398244767444" CI_END="-10.131573190543731" CI_START="-17.680099346640567" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.90583626859215" ESTIMABLE="YES" I2="22.36386239248412" I2_Q="22.36386239248412" ID="CMP-001.12" NO="12" P_CHI2="0.272030482346321" P_Q="0.272030482346321" P_Z="5.150773568242267E-13" Q="5.1522398244767444" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="425" TOTAL_2="407" UNITS="" WEIGHT="100.0" Z="7.221260865430809">
<NAME>Mental state: 4e. Average mental state (PANSS total endpoint score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.474704733839108" CI_START="-24.605295266160905" DF="0.0" EFFECT_SIZE="-16.040000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="1.0" P_Z="2.421974657064895E-4" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="19.416889527831355" Z="3.670372279660292">
<NAME>Ziprasidone 40mg - long term</NAME>
<CONT_DATA CI_END="-7.474704733839108" CI_START="-24.605295266160905" EFFECT_SIZE="-16.040000000000006" ESTIMABLE="YES" MEAN_1="87.49" MEAN_2="103.53" ORDER="312" SD_1="27.04" SD_2="26.48" SE="4.370128907328326" STUDY_ID="STD-Arato-1997" TOTAL_1="75" TOTAL_2="75" WEIGHT="19.416889527831355"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.477888632794171" CI_START="-14.657888632794178" DF="0.0" EFFECT_SIZE="-6.090000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="1.0" P_Z="0.1635805541487968" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="91" WEIGHT="19.405136925824845" Z="1.393129763634228">
<NAME>Ziprasidone 80mg - short term</NAME>
<CONT_DATA CI_END="2.477888632794171" CI_START="-14.657888632794178" EFFECT_SIZE="-6.090000000000003" ESTIMABLE="YES" MEAN_1="85.84" MEAN_2="91.93" ORDER="313" SD_1="31.69" SD_2="29.33" SE="4.3714520778833625" STUDY_ID="STD-Daniel-1999" TOTAL_1="104" TOTAL_2="91" WEIGHT="19.405136925824845"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.6394980665431245" CI_START="-24.060501933456862" DF="0.0" EFFECT_SIZE="-14.849999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.03" NO="3" P_CHI2="1.0" P_Z="0.0015775273338950607" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="16.79181887365946" Z="3.1600302980986377">
<NAME>Ziprasidone 80mg - long term</NAME>
<CONT_DATA CI_END="-5.6394980665431245" CI_START="-24.060501933456862" EFFECT_SIZE="-14.849999999999994" ESTIMABLE="YES" MEAN_1="88.68" MEAN_2="103.53" ORDER="314" SD_1="30.28" SD_2="26.48" SE="4.699322031480238" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="75" WEIGHT="16.79181887365946"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.593810484618163" CI_START="-20.886189515381854" DF="0.0" EFFECT_SIZE="-13.240000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.04" NO="4" P_CHI2="1.0" P_Z="6.892062674002998E-4" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="91" WEIGHT="24.365437901385032" Z="3.3938372967485115">
<NAME>Ziprasidone 160mg - short term</NAME>
<CONT_DATA CI_END="-5.593810484618164" CI_START="-20.886189515381854" EFFECT_SIZE="-13.240000000000009" ESTIMABLE="YES" MEAN_1="78.69" MEAN_2="91.93" ORDER="315" SD_1="24.37" SD_2="29.33" SE="3.9011887849440154" STUDY_ID="STD-Daniel-1999" TOTAL_1="103" TOTAL_2="91" WEIGHT="24.365437901385032"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-10.994858784065144" CI_START="-27.86514121593487" DF="0.0" EFFECT_SIZE="-19.430000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.05" NO="5" P_CHI2="1.0" P_Z="6.3407588034412E-6" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="20.020716771299302" Z="4.514696226741552">
<NAME>Ziprasidone 160mg - long term</NAME>
<CONT_DATA CI_END="-10.994858784065144" CI_START="-27.86514121593487" EFFECT_SIZE="-19.430000000000007" ESTIMABLE="YES" MEAN_1="84.1" MEAN_2="103.53" ORDER="316" SD_1="25.52" SD_2="26.48" SE="4.303722559429755" STUDY_ID="STD-Arato-1997" TOTAL_1="71" TOTAL_2="75" WEIGHT="20.020716771299302"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04475404056632146" CI_END="-0.008889924492326173" CI_START="-11.06390143260717" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.536395678549748" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="0.832457085540299" P_Q="0.832457085540299" P_Z="0.04963267268949586" Q="0.04475404056632146" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="94" UNITS="" WEIGHT="200.0" Z="1.9631162077317623">
<NAME>Mental state: 5a. Average change in negative symptoms (SANS total change score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.067556874481138" CI_START="-14.467556874481136" DF="0.0" EFFECT_SIZE="-6.199999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="1.0" P_Z="0.14161194422872309" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0" Z="1.4698147093074538">
<NAME>Ziprasidone 40mg</NAME>
<CONT_DATA CI_END="2.067556874481138" CI_START="-14.467556874481136" EFFECT_SIZE="-6.199999999999999" ESTIMABLE="YES" MEAN_1="-8.6" MEAN_2="-2.4" ORDER="317" SD_1="21.8" SD_2="17.8" SE="4.218218773250208" STUDY_ID="STD-Keck-1998" TOTAL_1="43" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.433018669251699" CI_START="-12.433018669251698" DF="0.0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="1.0" P_Z="0.18736401434659206" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0" Z="1.3184172351455756">
<NAME>Ziprasidone 120mg</NAME>
<CONT_DATA CI_END="2.433018669251699" CI_START="-12.433018669251698" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-7.4" MEAN_2="-2.4" ORDER="318" SD_1="17.7" SD_2="17.8" SE="3.7924261506244" STUDY_ID="STD-Keck-1998" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.227481335444347" CI_END="-2.5054268279544942" CI_START="-4.555387562090538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.530407195022516" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="0.5205038561576651" P_Q="0.5205038561576651" P_Z="1.4699905041645162E-11" Q="3.227481335444347" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="425" TOTAL_2="407" UNITS="" WEIGHT="100.0" Z="6.750832674774542">
<NAME>Mental state: 5b. Average negative symptom score (PANSS negative endpoint score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.8665182922627173" CI_START="-6.453481707737283" DF="0.0" EFFECT_SIZE="-4.16" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="1.0" P_Z="3.7790218485405367E-4" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="19.972872622755037" Z="3.555053501486483">
<NAME>Ziprasidone 40mg - long term</NAME>
<CONT_DATA CI_END="-1.8665182922627173" CI_START="-6.453481707737283" EFFECT_SIZE="-4.16" ESTIMABLE="YES" MEAN_1="22.85" MEAN_2="27.01" ORDER="319" SD_1="7.27" SD_2="7.06" SE="1.1701652304980978" STUDY_ID="STD-Arato-1997" TOTAL_1="75" TOTAL_2="75" WEIGHT="19.972872622755037"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5957389408885687" CI_START="-4.215738940888566" DF="0.0" EFFECT_SIZE="-1.8099999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="1.0" P_Z="0.1403165177460316" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="91" WEIGHT="18.15240186387957" Z="1.474613372100633">
<NAME>Ziprasidone 80mg - short term</NAME>
<CONT_DATA CI_END="0.5957389408885687" CI_START="-4.215738940888566" EFFECT_SIZE="-1.8099999999999987" ESTIMABLE="YES" MEAN_1="22.19" MEAN_2="24.0" ORDER="320" SD_1="8.84" SD_2="8.29" SE="1.2274403814890116" STUDY_ID="STD-Daniel-1999" TOTAL_1="104" TOTAL_2="91" WEIGHT="18.15240186387957"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9787429941563879" CI_START="-5.6012570058436175" DF="0.0" EFFECT_SIZE="-3.2900000000000027" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.03" NO="3" P_CHI2="1.0" P_Z="0.005271688458888968" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="19.66684126004933" Z="2.789945684462358">
<NAME>Ziprasidone 80mg - long term</NAME>
<CONT_DATA CI_END="-0.9787429941563879" CI_START="-5.6012570058436175" EFFECT_SIZE="-3.2900000000000027" ESTIMABLE="YES" MEAN_1="23.72" MEAN_2="27.01" ORDER="321" SD_1="7.23" SD_2="7.06" SE="1.1792344267927957" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="75" WEIGHT="19.66684126004933"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3402138130531513" CI_START="-5.75978618694685" DF="0.0" EFFECT_SIZE="-3.5500000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.04" NO="4" P_CHI2="1.0" P_Z="0.0016401918701070288" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="91" WEIGHT="21.51446666328462" Z="3.1486630635204294">
<NAME>Ziprasidone 160mg - short term</NAME>
<CONT_DATA CI_END="-1.3402138130531513" CI_START="-5.75978618694685" EFFECT_SIZE="-3.5500000000000007" ESTIMABLE="YES" MEAN_1="20.45" MEAN_2="24.0" ORDER="322" SD_1="7.29" SD_2="8.29" SE="1.1274626495065014" STUDY_ID="STD-Daniel-1999" TOTAL_1="103" TOTAL_2="91" WEIGHT="21.51446666328462"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.3868015911153586" CI_START="-6.8931984088846425" DF="0.0" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.05" NO="5" P_CHI2="1.0" P_Z="5.433690914169455E-5" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="20.693417590031437" Z="4.036143844415193">
<NAME>Ziprasidone 160mg - long term</NAME>
<CONT_DATA CI_END="-2.3868015911153586" CI_START="-6.8931984088846425" EFFECT_SIZE="-4.640000000000001" ESTIMABLE="YES" MEAN_1="22.37" MEAN_2="27.01" ORDER="323" SD_1="6.83" SD_2="7.06" SE="1.149612149334163" STUDY_ID="STD-Arato-1997" TOTAL_1="71" TOTAL_2="75" WEIGHT="20.693417590031437"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.0668765169695895" CI_END="0.934962662442741" CI_START="0.653758631418359" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7818183360767587" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="115" I2="34.06821469315146" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.0292057322492602" LOG_CI_START="-0.18458256420097002" LOG_EFFECT_SIZE="-0.10689414822511509" METHOD="MH" NO="15" P_CHI2="0.19420939605932197" P_Q="0.0" P_Z="0.0070013199710981236" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="940" TOTAL_2="399" WEIGHT="399.99999999999994" Z="2.6967814705402895">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0020982172598101234" CI_END="1.0485419042230681" CI_START="0.6908718851013027" DF="1.0" EFFECT_SIZE="0.8511216845894015" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="71" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.02058579141480248" LOG_CI_START="-0.16060248048704998" LOG_EFFECT_SIZE="-0.07000834453612376" NO="1" P_CHI2="0.9634646469094017" P_Z="0.12987385640199986" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="99.99999999999999" Z="1.5145995098667437">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.092180505063683" CI_START="0.6587637812358954" EFFECT_SIZE="0.8482269503546099" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="47" LOG_CI_END="0.038294420305339374" LOG_CI_START="-0.18127028631131512" LOG_EFFECT_SIZE="-0.07148793300298786" ORDER="324" O_E="0.0" SE="0.1289733955294493" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.016634136754395772" WEIGHT="67.53292398023527"/>
<DICH_DATA CI_END="1.2399345729913502" CI_START="0.5925263264323428" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="24" LOG_CI_END="0.09339876956668663" LOG_CI_START="-0.22729234882791305" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="325" O_E="0.0" SE="0.1883755503916259" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.035485347985347984" WEIGHT="32.46707601976472"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="33.72487768297945" CI_START="0.5690975055443624" DF="0.0" EFFECT_SIZE="4.380952380952381" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="1.527950383200772" LOG_CI_START="-0.24481331797749992" LOG_EFFECT_SIZE="0.641568532611636" NO="2" P_CHI2="1.0" P_Z="0.1560058180735688" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="92" WEIGHT="99.99999999999999" Z="1.4186337600406074">
<NAME>due to adverse events - short term</NAME>
<DICH_DATA CI_END="33.72487768297945" CI_START="0.5690975055443624" EFFECT_SIZE="4.380952380952381" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.527950383200772" LOG_CI_START="-0.24481331797749992" LOG_EFFECT_SIZE="0.641568532611636" ORDER="326" O_E="0.0" SE="1.0413301733939644" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="1.084368530020704" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1849336822755123" CI_START="0.2952990732648449" DF="0.0" EFFECT_SIZE="0.5915317559153176" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.07369404466869355" LOG_CI_START="-0.5297379159763221" LOG_EFFECT_SIZE="-0.22802193565381432" NO="3" P_CHI2="1.0" P_Z="0.13854174523891385" STUDIES="1" TAU2="0.0" TOTAL_1="219" TOTAL_2="75" WEIGHT="100.0" Z="1.4812433238997589">
<NAME>due to adverse events - long term</NAME>
<DICH_DATA CI_END="1.1849336822755123" CI_START="0.2952990732648449" EFFECT_SIZE="0.5915317559153176" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.07369404466869355" LOG_CI_START="-0.5297379159763221" LOG_EFFECT_SIZE="-0.22802193565381432" ORDER="327" O_E="0.0" SE="0.35445892071926177" STUDY_ID="STD-Arato-1997" TOTAL_1="219" TOTAL_2="75" VAR="0.1256411264774639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8663927796127788" CI_START="0.39999926697479843" DF="0.0" EFFECT_SIZE="0.5886904761904762" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="32" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="-0.06228517571259969" LOG_CI_START="-0.3979408045447672" LOG_EFFECT_SIZE="-0.23011299012868344" NO="4" P_CHI2="1.0" P_Z="0.007202003402062426" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="92" WEIGHT="99.99999999999999" Z="2.687356530240424">
<NAME>due to lack of efficacy</NAME>
<DICH_DATA CI_END="0.8663927796127788" CI_START="0.39999926697479843" EFFECT_SIZE="0.5886904761904762" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="32" LOG_CI_END="-0.06228517571259969" LOG_CI_START="-0.3979408045447672" LOG_EFFECT_SIZE="-0.23011299012868344" ORDER="328" O_E="0.0" SE="0.19716577789817458" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.03887434397419231" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0036922675860864" CI_END="1.0805191922035249" CI_START="0.9252639472996995" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9998827195783094" ESTIMABLE="YES" EVENTS_1="416" EVENTS_2="173" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.03363248523505112" LOG_CI_START="-0.03373435968905838" LOG_EFFECT_SIZE="-5.093722700362075E-5" METHOD="MH" NO="16" P_CHI2="0.6054120198749686" P_Q="0.0" P_Z="0.9976351336435356" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="215" WEIGHT="100.0" Z="0.0029639247767029803">
<NAME>Side effects: 1. Any adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.016646593699331656" CI_END="1.1270447659330245" CI_START="0.9417401980638328" DF="1.0" EFFECT_SIZE="1.030234614588625" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="115" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.0519411664556691" LOG_CI_START="-0.026068891378417128" LOG_EFFECT_SIZE="0.012936137538626002" NO="1" P_CHI2="0.8973404991872547" P_Z="0.5156740939710709" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="64.50133107686227" Z="0.6500280701928945">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1300348793022938" CI_START="0.9313962627021545" EFFECT_SIZE="1.025919228450874" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="79" LOG_CI_END="0.0530918484876157" LOG_CI_START="-0.030865509039198928" LOG_EFFECT_SIZE="0.011113169724208375" ORDER="329" O_E="0.0" SE="0.049316967406873295" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.002432163274210603" WEIGHT="45.13638091249313"/>
<DICH_DATA CI_END="1.2660348627579354" CI_START="0.8548023767091592" EFFECT_SIZE="1.0402930402930404" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="36" LOG_CI_END="0.10244566499802575" LOG_CI_START="-0.06813427898546241" LOG_EFFECT_SIZE="0.01715569300628167" ORDER="330" O_E="0.0" SE="0.10019950348024173" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.010039940497686976" WEIGHT="19.364950164369148"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0938575778792765" CI_START="0.8159386309978343" DF="0.0" EFFECT_SIZE="0.944733112895607" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="58" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.03896077979663627" LOG_CI_START="-0.08834250450749784" LOG_EFFECT_SIZE="-0.02469086235543078" NO="2" P_CHI2="1.0" P_Z="0.4470860154295847" STUDIES="1" TAU2="0.0" TOTAL_1="219" TOTAL_2="75" WEIGHT="35.49866892313772" Z="0.7602820497272688">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.0938575778792765" CI_START="0.8159386309978343" EFFECT_SIZE="0.944733112895607" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="58" LOG_CI_END="0.03896077979663627" LOG_CI_START="-0.08834250450749784" LOG_EFFECT_SIZE="-0.02469086235543078" ORDER="331" O_E="0.0" SE="0.07477857936166875" STUDY_ID="STD-Arato-1997" TOTAL_1="219" TOTAL_2="75" VAR="0.005591835931349392" WEIGHT="35.49866892313772"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22531004072792463" CI_END="3.331916692449333" CI_START="0.8166825533489612" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.649581229262611" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.522694134252801" LOG_CI_START="-0.0879467220718456" LOG_EFFECT_SIZE="0.21737370609047768" METHOD="MH" NO="17" P_CHI2="0.635023400887055" P_Q="0.0" P_Z="0.1628947482392892" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="140" WEIGHT="99.99999999999999" Z="1.395401669281117">
<NAME>Side effects: 2. Cardiovascular problems - dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2348713715484623" CI_START="0.7268020397317021" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" LOG_CI_END="0.5098570164614923" LOG_CI_START="-0.13858386253766905" LOG_EFFECT_SIZE="0.18563657696191166" ORDER="332" O_E="0.0" SE="0.38089738215822594" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.14508281573498963" WEIGHT="89.47057876951133"/>
<DICH_DATA CI_END="21.936522334854846" CI_START="0.3170822418786297" EFFECT_SIZE="2.6373626373626373" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3411677786400213" LOG_CI_START="-0.49882807985899646" LOG_EFFECT_SIZE="0.42116984939051244" ORDER="333" O_E="0.0" SE="1.0808226754087165" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="1.1681776556776557" WEIGHT="10.529421230488655"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.711206687857582" CI_END="1.336878616002894" CI_START="0.7183621323694314" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9799811086500255" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.12609197660132895" LOG_CI_START="-0.14365656906966243" LOG_EFFECT_SIZE="-0.008782296234166745" METHOD="MH" NO="18" P_CHI2="0.5680875863537334" P_Q="0.0" P_Z="0.8984477687215358" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1295" TOTAL_2="608" WEIGHT="500.0" Z="0.12762244391503053">
<NAME>Side effects: 3. Gastrointestinal problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7316046109846446" CI_END="1.5886730559745907" CI_START="0.4931132676290749" DF="1.0" EFFECT_SIZE="0.8850964703499267" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="15" I2="42.250096029060074" ID="CMP-001.18.01" LOG_CI_END="0.20103452993508542" LOG_CI_START="-0.3070533122517096" LOG_EFFECT_SIZE="-0.05300939115831213" NO="1" P_CHI2="0.18820620642455443" P_Z="0.6825612301769501" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="0.408970610536636">
<NAME>constipation</NAME>
<DICH_DATA CI_END="1.3513091738682552" CI_START="0.37062458544049803" EFFECT_SIZE="0.7076923076923077" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.13075472514584072" LOG_CI_START="-0.4310657750684037" LOG_EFFECT_SIZE="-0.15015552496128148" ORDER="334" O_E="0.0" SE="0.3300161428821755" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.10891065456282847" WEIGHT="87.3481357352325"/>
<DICH_DATA CI_END="9.546374660373054" CI_START="0.466316945875885" EFFECT_SIZE="2.10989010989011" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9798384748384819" LOG_CI_START="-0.33131880207356973" LOG_EFFECT_SIZE="0.32425983638245603" ORDER="335" O_E="0.0" SE="0.7701802747913346" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.5931776556776557" WEIGHT="12.65186426476749"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.37923468951844" CI_START="0.1304137619368647" DF="0.0" EFFECT_SIZE="2.6630434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="1.7354330912165807" LOG_CI_START="-0.8846765771786262" LOG_EFFECT_SIZE="0.4253782570189772" NO="2" P_CHI2="1.0" P_Z="0.5245121797499321" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="0.6364054708246372">
<NAME>diarrhoea</NAME>
<DICH_DATA CI_END="54.37923468951844" CI_START="0.1304137619368646" EFFECT_SIZE="2.6630434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7354330912165807" LOG_CI_START="-0.8846765771786266" LOG_EFFECT_SIZE="0.4253782570189772" ORDER="336" O_E="0.0" SE="1.5390653889673769" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="2.368722271517303" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.00797895294209319" CI_END="2.575427717985026" CI_START="0.6955113501058738" DF="1.0" EFFECT_SIZE="1.3383718501357742" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="11" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="0.4108493654684868" LOG_CI_START="-0.15769577832739262" LOG_EFFECT_SIZE="0.1265767935705471" NO="3" P_CHI2="0.9288236386332764" P_Z="0.3828241659193412" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="0.87270451391245">
<NAME>dyspepsia</NAME>
<DICH_DATA CI_END="2.81510336222998" CI_START="0.6135998279676647" EFFECT_SIZE="1.3142857142857143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.4494943454829246" LOG_CI_START="-0.21211477082032776" LOG_EFFECT_SIZE="0.11868978733129844" ORDER="337" O_E="0.0" SE="0.388632469934475" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.1510351966873706" WEIGHT="73.9066861624352"/>
<DICH_DATA CI_END="5.05905794431238" CI_START="0.3910817059718339" EFFECT_SIZE="1.4065934065934067" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.7040696536625721" LOG_CI_START="-0.4077324990090225" LOG_EFFECT_SIZE="0.1481685773267748" ORDER="338" O_E="0.0" SE="0.6530780879887098" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.426510989010989" WEIGHT="26.0933138375648"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09431969115304505" CI_END="2.5479281677386556" CI_START="0.6397364490149973" DF="1.0" EFFECT_SIZE="1.2767155197515285" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="0.40618718002341064" LOG_CI_START="-0.19399890462849131" LOG_EFFECT_SIZE="0.10609413769745962" NO="4" P_CHI2="0.7587557763018488" P_Z="0.48835930664890015" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="0.6929207263392531">
<NAME>nausea</NAME>
<DICH_DATA CI_END="2.605123366705059" CI_START="0.5571525961940595" EFFECT_SIZE="1.2047619047619047" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.4158282943190925" LOG_CI_START="-0.2540258414352952" LOG_EFFECT_SIZE="0.08090122644189864" ORDER="339" O_E="0.0" SE="0.3934756351735764" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.1548230754752494" WEIGHT="80.94729690381442"/>
<DICH_DATA CI_END="7.54282379801143" CI_START="0.33197718416867517" EFFECT_SIZE="1.5824175824175823" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.8775339626217994" LOG_CI_START="-0.4788917630734873" LOG_EFFECT_SIZE="0.19932109977415602" ORDER="340" O_E="0.0" SE="0.7967711856890423" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.6348443223443223" WEIGHT="19.052703096185578"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12679320126120935" CI_END="1.0890855886456867" CI_START="0.3199387926674799" DF="1.0" EFFECT_SIZE="0.5902886822079961" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" ID="CMP-001.18.05" LOG_CI_END="0.037062011267179486" LOG_CI_START="-0.49493309839665234" LOG_EFFECT_SIZE="-0.22893554356473644" NO="5" P_CHI2="0.7217804814164813" P_Z="0.0916268154228995" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="99.99999999999999" Z="1.6868779882263252">
<NAME>vomiting</NAME>
<DICH_DATA CI_END="1.0833158284061297" CI_START="0.29286732157140977" EFFECT_SIZE="0.563265306122449" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.0347550887010165" LOG_CI_START="-0.5333290846276084" LOG_EFFECT_SIZE="-0.24928699796329595" ORDER="341" O_E="0.0" SE="0.33369545547524454" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.11135265700483091" WEIGHT="88.14470346660224"/>
<DICH_DATA CI_END="4.5745413054078625" CI_START="0.13684680266107285" EFFECT_SIZE="0.7912087912087912" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6603475533713532" LOG_CI_START="-0.8637653451510036" LOG_EFFECT_SIZE="-0.10170889588982515" ORDER="342" O_E="0.0" SE="0.8952714610725558" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.8015109890109889" WEIGHT="11.855296533397752"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.505055876521272" CI_END="1.6158174274442993" CI_START="0.9512195480219283" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2397568806098724" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="65" I2="17.270225622336977" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.2083922879157611" LOG_CI_START="-0.021719233335935142" LOG_EFFECT_SIZE="0.09333652728991298" METHOD="MH" NO="19" P_CHI2="0.2696248511149454" P_Q="0.0" P_Z="0.11183956081708397" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1906" TOTAL_2="871" WEIGHT="900.0" Z="1.589978901840152">
<NAME>Side effects: 4a. Movement disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1877840220662432" CI_END="1.1652003707089675" CI_START="0.3375129045633221" DF="1.0" EFFECT_SIZE="0.6271125588889472" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="54.29164899670698" ID="CMP-001.19.01" LOG_CI_END="0.06640061412661612" LOG_CI_START="-0.47170961757813834" LOG_EFFECT_SIZE="-0.20265450172576108" NO="1" P_CHI2="0.13910940516972792" P_Z="0.13987388905137232" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="1.4762608152945573">
<NAME>agitation - short term</NAME>
<DICH_DATA CI_END="1.7194194537131224" CI_START="0.402960457607002" EFFECT_SIZE="0.8323809523809523" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.23538183608867796" LOG_CI_START="-0.3947375689597481" LOG_EFFECT_SIZE="-0.07967786643553505" ORDER="343" O_E="0.0" SE="0.37013525766680533" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.13700010896807235" WEIGHT="63.90216991541008"/>
<DICH_DATA CI_END="1.0083047479867207" CI_START="0.06898392271627" EFFECT_SIZE="0.26373626373626374" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.0035918122348385854" LOG_CI_START="-1.1612521134538139" LOG_EFFECT_SIZE="-0.5788301506094875" ORDER="344" O_E="0.0" SE="0.6842350880199405" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.4681776556776557" WEIGHT="36.09783008458992"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3911020782081764" CI_START="0.41955083412569305" DF="0.0" EFFECT_SIZE="0.7639620653319283" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.14335899942120986" LOG_CI_START="-0.37721541113380785" LOG_EFFECT_SIZE="-0.11692820585629897" NO="2" P_CHI2="1.0" P_Z="0.37860476653648434" STUDIES="1" TAU2="0.0" TOTAL_1="219" TOTAL_2="75" WEIGHT="99.99999999999999" Z="0.8804699870317991">
<NAME>agitation - long term</NAME>
<DICH_DATA CI_END="1.3911020782081764" CI_START="0.41955083412569305" EFFECT_SIZE="0.7639620653319283" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" LOG_CI_END="0.14335899942120986" LOG_CI_START="-0.37721541113380785" LOG_EFFECT_SIZE="-0.11692820585629897" ORDER="345" O_E="0.0" SE="0.3057879856449091" STUDY_ID="STD-Arato-1997" TOTAL_1="219" TOTAL_2="75" VAR="0.09350629216477115" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5508304469244243" CI_END="3.308829029420349" CI_START="0.7884388935497628" DF="1.0" EFFECT_SIZE="1.6151809492751936" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="9" I2="35.51841840717147" ID="CMP-001.19.03" LOG_CI_END="0.5196743272995917" LOG_CI_START="-0.10323196019495931" LOG_EFFECT_SIZE="0.20822118355231617" NO="3" P_CHI2="0.21301336971936546" P_Z="0.19008463246128832" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="99.99999999999999" Z="1.3103287886925163">
<NAME>akathisia - short term</NAME>
<DICH_DATA CI_END="4.768897445533117" CI_START="0.876461096963786" EFFECT_SIZE="2.0444444444444443" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="6" LOG_CI_END="0.678417983092714" LOG_CI_START="-0.05726735595229085" LOG_EFFECT_SIZE="0.31057531357021156" ORDER="346" O_E="0.0" SE="0.43214520985619675" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.1867494824016563" WEIGHT="67.99282569704874"/>
<DICH_DATA CI_END="3.0149011188348136" CI_START="0.16406052250866932" EFFECT_SIZE="0.7032967032967034" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4792730729442905" LOG_CI_START="-0.7849959096187032" LOG_EFFECT_SIZE="-0.1528614183372064" ORDER="347" O_E="0.0" SE="0.7426378585898977" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.5515109890109889" WEIGHT="32.00717430295124"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8898571837230245" CI_START="0.472278471762691" DF="0.0" EFFECT_SIZE="1.1682539682539683" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="0.0" ID="CMP-001.19.04" LOG_CI_END="0.4608763805234658" LOG_CI_START="-0.3258018507556314" LOG_EFFECT_SIZE="0.06753726488391718" NO="4" P_CHI2="1.0" P_Z="0.7364708610312456" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="92" WEIGHT="100.0" Z="0.336530493723188">
<NAME>akathisia - use of beta blockers for akathisia - short term</NAME>
<DICH_DATA CI_END="2.8898571837230245" CI_START="0.472278471762691" EFFECT_SIZE="1.1682539682539683" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.4608763805234658" LOG_CI_START="-0.3258018507556314" LOG_EFFECT_SIZE="0.06753726488391718" ORDER="348" O_E="0.0" SE="0.46209868717339003" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.2135351966873706" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17183804525736568" CI_END="13.466913813003245" CI_START="0.6925777568227787" DF="1.0" EFFECT_SIZE="3.053994918125353" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" I2="0.0" ID="CMP-001.19.05" LOG_CI_END="1.1292680806858897" LOG_CI_START="-0.15953146058362655" LOG_EFFECT_SIZE="0.4848683100511315" NO="5" P_CHI2="0.6784837028763591" P_Z="0.14028149472117868" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="1.474743580384755">
<NAME>extrapyramidal problems - short term</NAME>
<DICH_DATA CI_END="30.670618032327152" CI_START="0.5068734654317634" EFFECT_SIZE="3.942857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.4867225273788014" LOG_CI_START="-0.29510044327687945" LOG_EFFECT_SIZE="0.5958110420509608" ORDER="349" O_E="0.0" SE="1.0466516331291014" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="1.095479641131815" WEIGHT="51.50691699604743"/>
<DICH_DATA CI_END="18.354401223161872" CI_START="0.24253780996105018" EFFECT_SIZE="2.10989010989011" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2637402210536595" LOG_CI_START="-0.6152205482887473" LOG_EFFECT_SIZE="0.32425983638245603" ORDER="350" O_E="0.0" SE="1.1037108569175424" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="1.2181776556776558" WEIGHT="48.49308300395257"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.80485077038586" CI_START="0.1691368217066495" DF="0.0" EFFECT_SIZE="1.5824175824175823" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.19.06" LOG_CI_END="1.170404034155268" LOG_CI_START="-0.7717618346069559" LOG_EFFECT_SIZE="0.19932109977415602" NO="6" P_CHI2="1.0" P_Z="0.6874666562114928" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="0.40229537878269517">
<NAME>hypertonia - short term</NAME>
<DICH_DATA CI_END="14.80485077038586" CI_START="0.1691368217066495" EFFECT_SIZE="1.5824175824175823" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.170404034155268" LOG_CI_START="-0.7717618346069559" LOG_EFFECT_SIZE="0.19932109977415602" ORDER="351" O_E="0.0" SE="1.1408378451870314" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="1.301510989010989" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.37923468951844" CI_START="0.1304137619368647" DF="0.0" EFFECT_SIZE="2.6630434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.19.07" LOG_CI_END="1.7354330912165807" LOG_CI_START="-0.8846765771786262" LOG_EFFECT_SIZE="0.4253782570189772" NO="7" P_CHI2="1.0" P_Z="0.5245121797499321" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="0.6364054708246372">
<NAME>rigidity - cogwheel - short term</NAME>
<DICH_DATA CI_END="54.37923468951844" CI_START="0.1304137619368646" EFFECT_SIZE="2.6630434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7354330912165807" LOG_CI_START="-0.8846765771786266" LOG_EFFECT_SIZE="0.4253782570189772" ORDER="352" O_E="0.0" SE="1.5390653889673769" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="2.368722271517303" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.72399569747103" CI_START="0.19653766694672525" DF="0.0" EFFECT_SIZE="3.7282608695652173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.19.08" LOG_CI_END="1.8495667890573664" LOG_CI_START="-0.7065542036629359" LOG_EFFECT_SIZE="0.5715062926972152" NO="8" P_CHI2="1.0" P_Z="0.38079581867407" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="0.8764309309415514">
<NAME>tremor - short term</NAME>
<DICH_DATA CI_END="70.72399569747108" CI_START="0.19653766694672514" EFFECT_SIZE="3.7282608695652173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8495667890573666" LOG_CI_START="-0.7065542036629361" LOG_EFFECT_SIZE="0.5715062926972152" ORDER="353" O_E="0.0" SE="1.5014781241268846" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="2.2544365572315885" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0234713602420967" CI_END="2.7110324686905862" CI_START="1.0326164405388558" DF="1.0" EFFECT_SIZE="1.6731577026701758" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="18" I2="0.0" ID="CMP-001.19.09" LOG_CI_END="0.4331347189411332" LOG_CI_START="0.013939035274892805" LOG_EFFECT_SIZE="0.22353687710801298" NO="9" P_CHI2="0.8782376894777237" P_Z="0.036590062821945435" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="99.99999999999999" Z="2.0903088720593406">
<NAME>use of anti-parkinsonian medication</NAME>
<DICH_DATA CI_END="3.078876316652543" CI_START="0.9562645276385162" EFFECT_SIZE="1.7158730158730158" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="12" LOG_CI_END="0.4883922429550988" LOG_CI_START="-0.01942195395564156" LOG_EFFECT_SIZE="0.2344851444997286" ORDER="354" O_E="0.0" SE="0.2982925729861844" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.08897845909871813" WEIGHT="67.99282569704874"/>
<DICH_DATA CI_END="3.721701042781736" CI_START="0.6728228238538716" EFFECT_SIZE="1.5824175824175823" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.5707414841400473" LOG_CI_START="-0.1720992845917352" LOG_EFFECT_SIZE="0.19932109977415602" ORDER="355" O_E="0.0" SE="0.4363483446741581" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.1903998778998779" WEIGHT="32.00717430295124"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.20" NO="20" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Side effects: 4b. Movement disorders (AIMS, skewed data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="76" STUDY_ID="STD-Arato-1997">
<TR>
<TD>
<P>Zip 40mg: n=75, mean endpoint = 1.89, SD=4.138. <BR/>Zip 80mg: n=72, mean endpoint = 2.03, SD = 3.516.<BR/>Zip 160mg: n=70, mean endpoint = 2.06, SD=3.438.<BR/>Placebo: n=73, mean endpoint = 3.32, SD=4.856.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="77" STUDY_ID="STD-Daniel-1999">
<TR>
<TD>
<P>Zip 80 mg/day: n=89, mean endpoint = 1.30, SD = 2.570.<BR/>Zip 160 mg/day: n=97, mean endpoint = 1.31, SD = 2.596.<BR/>Placebo: n=82, mean endpoint = 0.88, SD = 2.050.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="78" STUDY_ID="STD-Keck-1998">
<TR>
<TD>
<P>Zip 40mg/day: n=44, Mean endpoint = 1.25, SD 2.103.<BR/>Zip 120 mg/day: n=46, mean endpoint = 1.30, SD = 3.272.<BR/>Placebo: n=48, mean endpoint = 1.52, SD = 2.783.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.21" NO="21" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Side effects: 4c. Movement disorders (BAS, skewed data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="79" STUDY_ID="STD-Arato-1997">
<TR>
<TD>
<P>Zip 40mg/day: n=74, mean endpoint = 0.30, SD = 0.754.<BR/>Zip 80mg: n=72, mean endpoint = 0.50, SD = 0.979.<BR/>Zip 160mg: n=71, mean endpoint = 0.41, SD = 0.729.<BR/>Placebo: n=75, mean endpoint = 0.63, SD=1.075.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="80" STUDY_ID="STD-Daniel-1999">
<TR>
<TD>
<P>Zip 80mg/day: n=104, mean endpoint = 0.61, SD = 0.806.<BR/>Zip 160mg/day: n = 103, mean andpoint = 0.59, SD = 0.834.<BR/>PLacebo: n=91, mean endpoint = 0.34, SD = 0.619.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="81" STUDY_ID="STD-Keck-1998">
<TR>
<TD>
<P>Zip 40 mg/day: n=44, mean endpoint = 0.36, SD = 0.613.<BR/>Zip 120 mg/day: n=46, mean endpoint = 0.33, SD = 0.732.<BR/>Placebo: n=48, mean endpoint = 0.35, SD = 0.635.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.22" NO="22" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Side effects: 4d. Movement disorders (SAS, skewed data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="82" STUDY_ID="STD-Arato-1997">
<TR>
<TD>
<P>Zip 40mg: n=74, mean endpoint = 4.30, SD = 5.823.<BR/>Zip 80mg: n=72, mean endpoint = 4.44, SD=5.576.<BR/>Zip 160mg: n=71, mean endpoint = 4.83, SD=5.616.<BR/>Placebo: n=75, mean endpoint = 5.76, SD=6.214.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="83" STUDY_ID="STD-Daniel-1999">
<TR>
<TD>
<P>Zip 80 mg/day: n=104, mean endpoint = 1.73, SD = 2.742.<BR/>Zip 160 mg/day: n=103, mean endpoint = 1.89, SD = 2.697.<BR/>Placebo: n=90, mean endpoint = 1.97, SD = 3.251.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="84" STUDY_ID="STD-Keck-1998">
<TR>
<TD>
<P>Zip 40mg/day: n=44, mean endpoint = 1.07, SD = 1.336.<BR/>Zip 120 mg/day: n=46, mean endpoint = 1.07, SD = 1.583.<BR/>Placebo: n=48, mean endpoint = 1.67, SD = 3.103.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="8.806659754277797" CI_END="1.6526329335974037" CI_START="0.9261312899390874" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2371560413255807" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="48" I2="54.57982808911157" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.21817640310825503" LOG_CI_START="-0.03332744263300644" LOG_EFFECT_SIZE="0.09242448023762431" METHOD="MH" NO="23" P_CHI2="0.06611803341971012" P_Q="0.0" P_Z="0.14971922829797704" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="821" TOTAL_2="355" WEIGHT="300.0" Z="1.4405239174110853">
<NAME>Side effects: 5. Sleep problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8621409876775574" CI_END="1.3971210425222333" CI_START="0.4235657616570575" DF="1.0" EFFECT_SIZE="0.7692675987606862" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.14523403376074015" LOG_CI_START="-0.3730791527297362" LOG_EFFECT_SIZE="-0.11392255948449798" NO="1" P_CHI2="0.35314033277465584" P_Z="0.38891874050991304" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="0.8615799074227903">
<NAME>insomnia - short term</NAME>
<DICH_DATA CI_END="1.5720686476285683" CI_START="0.4515011610667472" EFFECT_SIZE="0.8424908424908425" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.19647150648414233" LOG_CI_START="-0.3453411285304686" LOG_EFFECT_SIZE="-0.07443481102316316" ORDER="365" O_E="0.0" SE="0.31826342382338074" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.10129160694378087" WEIGHT="87.3481357352325"/>
<DICH_DATA CI_END="2.835025557961074" CI_START="0.02453481119922909" EFFECT_SIZE="0.26373626373626374" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.45255697844283393" LOG_CI_START="-1.610217279661809" LOG_EFFECT_SIZE="-0.5788301506094875" ORDER="366" O_E="0.0" SE="1.2116838101079241" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="1.4681776556776558" WEIGHT="12.65186426476749"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6192631983694956" CI_START="0.765038997110375" DF="0.0" EFFECT_SIZE="1.1130136986301369" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="24" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.20931744560901358" LOG_CI_START="-0.1163164265481015" LOG_EFFECT_SIZE="0.04650050953045604" NO="2" P_CHI2="1.0" P_Z="0.5756393161662905" STUDIES="1" TAU2="0.0" TOTAL_1="219" TOTAL_2="75" WEIGHT="100.0" Z="0.5597656247411607">
<NAME>insomnia - long term</NAME>
<DICH_DATA CI_END="1.6192631983694956" CI_START="0.765038997110375" EFFECT_SIZE="1.1130136986301369" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="24" LOG_CI_END="0.20931744560901358" LOG_CI_START="-0.1163164265481015" LOG_EFFECT_SIZE="0.04650050953045604" ORDER="367" O_E="0.0" SE="0.1912789484187532" STUDY_ID="STD-Arato-1997" TOTAL_1="219" TOTAL_2="75" VAR="0.03658763610818405" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2106415751700204" CI_END="4.794706345768742" CI_START="1.1969656974730047" DF="1.0" EFFECT_SIZE="2.395641672984782" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="9" I2="68.85357718738676" ID="CMP-001.23.03" LOG_CI_END="0.6807620137345163" LOG_CI_START="0.07808170461555734" LOG_EFFECT_SIZE="0.3794218591750368" NO="3" P_CHI2="0.07316084010234303" P_Z="0.013593875971480667" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="2.467819730222897">
<NAME>somnolence - short term</NAME>
<DICH_DATA CI_END="8.592927722883852" CI_START="1.4294727484275762" EFFECT_SIZE="3.5047619047619047" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="5" LOG_CI_END="0.9341411588558166" LOG_CI_START="0.15517588035134255" LOG_EFFECT_SIZE="0.5446585196035796" ORDER="368" O_E="0.0" SE="0.45756806053384447" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.20936853002070394" WEIGHT="57.03890135142529"/>
<DICH_DATA CI_END="2.9970384271501493" CI_START="0.2843043313019462" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.47669231137816925" LOG_CI_START="-0.546216523896593" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="369" O_E="0.0" SE="0.6008617133207927" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.36103479853479853" WEIGHT="42.96109864857471"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.315906545031364" CI_END="1.2462462633181108" CI_START="0.7827254908509205" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9876581990632153" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="80" I2="14.125372970097072" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.09560386915501164" LOG_CI_START="-0.10639052237581635" LOG_EFFECT_SIZE="-0.005393326610402353" METHOD="MH" NO="24" P_CHI2="0.3163514437555861" P_Q="0.0" P_Z="0.91664277916112" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1423" TOTAL_2="635" WEIGHT="800.0" Z="0.10466355855862279">
<NAME>Side effects: 6. Other problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3482359460976285" CI_START="0.3775599504471192" DF="0.0" EFFECT_SIZE="0.7134703196347032" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.1297659019332685" LOG_CI_START="-0.42301407958127957" LOG_EFFECT_SIZE="-0.14662408882400552" NO="1" P_CHI2="1.0" P_Z="0.2984536571941879" STUDIES="1" TAU2="0.0" TOTAL_1="219" TOTAL_2="75" WEIGHT="100.0" Z="1.0397552117342348">
<NAME>anxiety - long term</NAME>
<DICH_DATA CI_END="1.3482359460976285" CI_START="0.3775599504471192" EFFECT_SIZE="0.7134703196347032" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.1297659019332685" LOG_CI_START="-0.42301407958127957" LOG_EFFECT_SIZE="-0.14662408882400552" ORDER="370" O_E="0.0" SE="0.3247056974466846" STUDY_ID="STD-Arato-1997" TOTAL_1="219" TOTAL_2="75" VAR="0.10543378995433789" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.72399569747103" CI_START="0.19653766694672525" DF="0.0" EFFECT_SIZE="3.7282608695652173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="1.8495667890573664" LOG_CI_START="-0.7065542036629359" LOG_EFFECT_SIZE="0.5715062926972152" NO="2" P_CHI2="1.0" P_Z="0.38079581867407" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="0.8764309309415514">
<NAME>asthenia - short term</NAME>
<DICH_DATA CI_END="70.72399569747108" CI_START="0.19653766694672514" EFFECT_SIZE="3.7282608695652173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8495667890573666" LOG_CI_START="-0.7065542036629361" LOG_EFFECT_SIZE="0.5715062926972152" ORDER="371" O_E="0.0" SE="1.5014781241268846" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="2.2544365572315885" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.380955109038808" CI_START="0.644251675056787" DF="0.0" EFFECT_SIZE="1.861904761904762" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="0.7308593689321925" LOG_CI_START="-0.1909444436082974" LOG_EFFECT_SIZE="0.26995746266194753" NO="3" P_CHI2="1.0" P_Z="0.2509761824730875" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="92" WEIGHT="99.99999999999999" Z="1.147981592128624">
<NAME>dry mouth - short term</NAME>
<DICH_DATA CI_END="5.380955109038808" CI_START="0.644251675056787" EFFECT_SIZE="1.861904761904762" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.7308593689321925" LOG_CI_START="-0.1909444436082974" LOG_EFFECT_SIZE="0.26995746266194753" ORDER="372" O_E="0.0" SE="0.541472122488747" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.2931920594324687" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.102043908085123" CI_START="0.41824987553414317" DF="0.0" EFFECT_SIZE="1.139047619047619" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-001.24.04" LOG_CI_END="0.4916479407709847" LOG_CI_START="-0.3785641796060768" LOG_EFFECT_SIZE="0.05654188058245398" NO="4" P_CHI2="1.0" P_Z="0.7989574154002249" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="92" WEIGHT="100.0" Z="0.2546966353715144">
<NAME>pain - abdominal - short term</NAME>
<DICH_DATA CI_END="3.102043908085123" CI_START="0.41824987553414317" EFFECT_SIZE="1.139047619047619" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.4916479407709847" LOG_CI_START="-0.3785641796060768" LOG_EFFECT_SIZE="0.05654188058245398" ORDER="373" O_E="0.0" SE="0.5111669071289542" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.2612916069437809" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0683038922204553" CI_START="0.4990450517959848" DF="0.0" EFFECT_SIZE="0.7301587301587301" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="30" I2="0.0" ID="CMP-001.24.05" LOG_CI_END="0.028694810689887978" LOG_CI_START="-0.3018602462339033" LOG_EFFECT_SIZE="-0.13658271777200764" NO="5" P_CHI2="1.0" P_Z="0.1053003838458513" STUDIES="1" TAU2="0.0" TOTAL_1="210" TOTAL_2="92" WEIGHT="100.0" Z="1.619683027904491">
<NAME>pain - headache - short term</NAME>
<DICH_DATA CI_END="1.0683038922204553" CI_START="0.4990450517959848" EFFECT_SIZE="0.7301587301587301" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="30" LOG_CI_END="0.028694810689887978" LOG_CI_START="-0.3018602462339033" LOG_EFFECT_SIZE="-0.13658271777200764" ORDER="374" O_E="0.0" SE="0.19416967671095625" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.03770186335403727" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07542025241926668" CI_END="1.4290809412110344" CI_START="0.6419484428415935" DF="1.0" EFFECT_SIZE="0.9578080626644475" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="26" I2="0.0" ID="CMP-001.24.06" LOG_CI_END="0.1550568273394671" LOG_CI_START="-0.19249985026218167" LOG_EFFECT_SIZE="-0.018721511461357292" NO="6" P_CHI2="0.7836024595849801" P_Z="0.8327693634789618" STUDIES="2" TAU2="0.0" TOTAL_1="301" TOTAL_2="140" WEIGHT="100.0" Z="0.21115110464066691">
<NAME>pain - site not specified - short term</NAME>
<DICH_DATA CI_END="1.9746103255971363" CI_START="0.388790507481385" EFFECT_SIZE="0.8761904761904762" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.2954814036889226" LOG_CI_START="-0.41028434713768824" LOG_EFFECT_SIZE="-0.057401471724382806" ORDER="375" O_E="0.0" SE="0.41457029563236186" STUDY_ID="STD-Daniel-1999" TOTAL_1="210" TOTAL_2="92" VAR="0.17186853002070393" WEIGHT="32.06828930672511"/>
<DICH_DATA CI_END="1.5654363034082142" CI_START="0.6341282670579332" EFFECT_SIZE="0.9963369963369964" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.19463540115055947" LOG_CI_START="-0.19782288716367413" LOG_EFFECT_SIZE="-0.001593743006557322" ORDER="376" O_E="0.0" SE="0.23053194125563944" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.05314497593909359" WEIGHT="67.93171069327488"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.117208871633418" CI_START="0.6254750079844766" DF="0.0" EFFECT_SIZE="2.10989010989011" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-001.24.07" LOG_CI_END="0.8523097114313554" LOG_CI_START="-0.2037900386664434" LOG_EFFECT_SIZE="0.32425983638245603" NO="7" P_CHI2="1.0" P_Z="0.22876125249222157" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="1.2035560104689191">
<NAME>respiratory problems - short term</NAME>
<DICH_DATA CI_END="7.117208871633416" CI_START="0.6254750079844769" EFFECT_SIZE="2.10989010989011" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.8523097114313554" LOG_CI_START="-0.20379003866644327" LOG_EFFECT_SIZE="0.32425983638245603" ORDER="377" O_E="0.0" SE="0.6203582209855224" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="0.3848443223443223" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="136.96553701782392" CI_START="0.46600193372485954" DF="0.0" EFFECT_SIZE="7.989130434782608" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.24.08" LOG_CI_END="2.136611304632143" LOG_CI_START="-0.3316122811548634" LOG_EFFECT_SIZE="0.9024995117386396" NO="8" P_CHI2="1.0" P_Z="0.15176885687306305" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="100.0" Z="1.4333114303408663">
<NAME>skin problems - short term</NAME>
<DICH_DATA CI_END="136.96553701782392" CI_START="0.4660019337248593" EFFECT_SIZE="7.989130434782608" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.136611304632143" LOG_CI_START="-0.3316122811548636" LOG_EFFECT_SIZE="0.9024995117386396" ORDER="378" O_E="0.0" SE="1.449846752195085" STUDY_ID="STD-Keck-1998" TOTAL_1="91" TOTAL_2="48" VAR="2.1020556048506363" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9087232823872617" CI_END="2.2827039625759213" CI_START="-2.7629983519921004" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2401471947080896" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.25" NO="25" P_CHI2="0.6348531328049367" P_Q="0.6348531328049367" P_Z="0.8520004283814283" Q="0.9087232823872617" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="210" UNITS="" WEIGHT="100.00000000000001" Z="0.18656663563255807">
<NAME>Side effects 7: Body weight (kg) - long term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1428797923333472E-32" CI_END="5.16087755326846" CI_START="-2.9808775532684813" DF="0.0" EFFECT_SIZE="1.089999999999989" ESTIMABLE="YES" I2="100.0" ID="CMP-001.25.01" NO="1" P_CHI2="0.0" P_Z="0.5997283472130337" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="38.40671640253255" Z="0.5247912066117962">
<NAME>Ziprasidone 40mg</NAME>
<CONT_DATA CI_END="5.16087755326846" CI_START="-2.9808775532684813" EFFECT_SIZE="1.0899999999999892" ESTIMABLE="YES" MEAN_1="69.99" MEAN_2="68.9" ORDER="379" SD_1="12.47" SD_2="12.28" SE="2.0770165091700834" STUDY_ID="STD-Arato-1997" TOTAL_1="72" TOTAL_2="70" WEIGHT="38.40671640253255"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0340027992265959E-32" CI_END="2.4998392693314697" CI_START="-6.059839269331472" DF="0.0" EFFECT_SIZE="-1.7800000000000014" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.25.02" NO="2" P_CHI2="0.0" P_Z="0.41498313033399026" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="70" WEIGHT="34.74788209199307" Z="0.8151558207993767">
<NAME>Ziprasidone 80mg</NAME>
<CONT_DATA CI_END="2.4998392693314697" CI_START="-6.059839269331472" EFFECT_SIZE="-1.7800000000000011" ESTIMABLE="YES" MEAN_1="67.12" MEAN_2="68.9" ORDER="380" SD_1="13.43" SD_2="12.28" SE="2.1836315886874944" STUDY_ID="STD-Arato-1997" TOTAL_1="69" TOTAL_2="70" WEIGHT="34.74788209199307"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.719189501638919" CI_START="-5.01918950163893" DF="0.0" EFFECT_SIZE="-0.15000000000000568" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.03" NO="3" P_CHI2="1.0" P_Z="0.9518541427737173" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="26.84540150547439" Z="0.060378549157321444">
<NAME>Ziprasidone 160mg</NAME>
<CONT_DATA CI_END="4.719189501638919" CI_START="-5.01918950163893" EFFECT_SIZE="-0.15000000000000568" ESTIMABLE="YES" MEAN_1="68.75" MEAN_2="68.9" ORDER="381" SD_1="16.77" SD_2="12.28" SE="2.4843260080524283" STUDY_ID="STD-Arato-1997" TOTAL_1="70" TOTAL_2="70" WEIGHT="26.84540150547439"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>ZIPRASIDONE versus TYPICAL ANTIPSYCHOTICS</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14482583617010475" CI_START="-0.44482583617010457" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1499999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.31867687985004345" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="117" UNITS="" WEIGHT="99.99999999999999" Z="0.9971805778628672">
<NAME>Global impression: Average score (CGI-S - long term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14482583617010475" CI_START="-0.44482583617010457" EFFECT_SIZE="-0.1499999999999999" ESTIMABLE="YES" MEAN_1="3.66" MEAN_2="3.81" ORDER="382" SD_1="1.18" SD_2="1.08" SE="0.15042410906305076" STUDY_ID="STD-Hirsch-1999" TOTAL_1="110" TOTAL_2="117" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0027962381501372" CI_START="0.7400894999046819" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8614864864864865" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.0012126960942148459" LOG_CI_START="-0.13071575734418164" LOG_EFFECT_SIZE="-0.0647515306249834" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.05436314302311464" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.9239317169449017">
<NAME>Mental state: 1. No clinically important response (&gt;20% decrease in PANSS negative subscale)</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0027962381501372" CI_START="0.7400894999046819" EFFECT_SIZE="0.8614864864864865" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="114" LOG_CI_END="0.0012126960942148459" LOG_CI_START="-0.13071575734418164" LOG_EFFECT_SIZE="-0.0647515306249834" ORDER="383" O_E="0.0" SE="0.07749542660609093" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.006005541144860027" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7758022476382838" CI_END="2.131885722682546" CI_START="0.56591784302303" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0983952702702702" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="43.68742345438839" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.3287639211150724" LOG_CI_START="-0.24724661282509133" LOG_EFFECT_SIZE="0.040758654144990525" METHOD="MH" NO="3" P_CHI2="0.18266576034019688" P_Q="0.0" P_Z="0.7814920875774991" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="296" TOTAL_2="306" WEIGHT="200.0" Z="0.2773751154724686">
<NAME>Mental state: 2. Relapse of positive symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7855776253125537" CI_START="0.33666907238369215" DF="0.0" EFFECT_SIZE="0.7753378378378378" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.2517787352412582" LOG_CI_START="-0.4727967776125753" LOG_EFFECT_SIZE="-0.11050902118565854" NO="1" P_CHI2="1.0" P_Z="0.5499400899679368" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.5978499070099197">
<NAME>hallucinations</NAME>
<DICH_DATA CI_END="1.7855776253125535" CI_START="0.33666907238369226" EFFECT_SIZE="0.7753378378378378" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.2517787352412581" LOG_CI_START="-0.4727967776125752" LOG_EFFECT_SIZE="-0.11050902118565854" ORDER="384" O_E="0.0" SE="0.425619242956976" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.18115173997526937" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.720324567100201" CI_START="0.6361055338584406" DF="0.0" EFFECT_SIZE="2.0675675675675675" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.8273902483955959" LOG_CI_START="-0.19647082622235082" LOG_EFFECT_SIZE="0.31545971108662263" NO="2" P_CHI2="1.0" P_Z="0.22713927811895862" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.2077608723115205">
<NAME>psychosis</NAME>
<DICH_DATA CI_END="6.720324567100201" CI_START="0.6361055338584406" EFFECT_SIZE="2.0675675675675675" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8273902483955959" LOG_CI_START="-0.19647082622235082" LOG_EFFECT_SIZE="0.31545971108662263" ORDER="385" O_E="0.0" SE="0.6014210634246401" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.361707295530825" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3. Average change (BPRS total change scores, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA ORDER="106" STUDY_ID="STD-Brook-1998">
<TR>
<TD>
<P>1. Ziprasidone: mean change -8.8, SD 11.8. N=83.<BR/>2. Haloperidol: mean change -5.8, SD 9.4. N=40.<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.189566365729044" CI_START="-6.509566365729037" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1599999999999966" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6708376956571167" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="117" UNITS="" WEIGHT="100.0" Z="0.424998601126171">
<NAME>Mental state: 4. Average score (PANSS total endpoint scores - long term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.189566365729044" CI_START="-6.509566365729037" EFFECT_SIZE="-1.1599999999999966" ESTIMABLE="YES" MEAN_1="64.42" MEAN_2="65.58" ORDER="387" SD_1="22.04" SD_2="18.84" SE="2.7294207485064708" STUDY_ID="STD-Hirsch-1999" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7268393044279049" CI_START="-1.346839304427906" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3100000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5578748678462611" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="117" UNITS="" WEIGHT="100.0" Z="0.5860009671823405">
<NAME>Mental state: 5. Average score (BPRSd core endpoint scores - long term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7268393044279049" CI_START="-1.346839304427906" EFFECT_SIZE="-0.3100000000000005" ESTIMABLE="YES" MEAN_1="8.18" MEAN_2="8.49" ORDER="388" SD_1="4.06" SD_2="3.9" SE="0.5290093657875152" STUDY_ID="STD-Hirsch-1999" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1811930696879815" CI_START="-2.3811930696879844" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5091129870812481" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="117" UNITS="" WEIGHT="100.0" Z="0.6602194959864935">
<NAME>Mental state: 6. Negative symptoms scores (PANSS negative endpoint scores - long term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1811930696879815" CI_START="-2.3811930696879844" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="18.99" MEAN_2="19.59" ORDER="389" SD_1="7.55" SD_2="6.0" SE="0.9087886735357418" STUDY_ID="STD-Hirsch-1999" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.08" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 7. Depression scores (MADRS total endpoint scores - long term - skewed data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="110" STUDY_ID="STD-Hirsch-1999">
<TR>
<TD>
<P>Zip 80mg: n=108, mean endpoint = 13.35, SD = 9.344.<BR/>Haloperidol: n=117, mean endpoint = 13.54, SD = 7.900.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="15.514509026377066" CI_END="0.9456325887306429" CI_START="0.5967732360755488" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7512178246788905" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="95" I2="61.32652351551008" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.02427756939216319" LOG_CI_START="-0.224190662219941" LOG_EFFECT_SIZE="-0.12423411580605206" METHOD="MH" NO="9" P_CHI2="0.016611159363965955" P_Q="0.0" P_Z="0.014850583665175127" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1109" TOTAL_2="596" WEIGHT="500.0" Z="2.4360024567356096">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.034510139469376526" CI_END="0.7207258763348471" CI_START="0.3524482615094987" DF="1.0" EFFECT_SIZE="0.5040025616394492" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="44" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="-0.1422298851173378" LOG_CI_START="-0.4529046272969679" LOG_EFFECT_SIZE="-0.29756725620715285" NO="1" P_CHI2="0.8526259347735572" P_Z="1.736568453648023E-4" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="142" WEIGHT="100.0" Z="3.754544711634188">
<NAME>any reason - immediate term</NAME>
<DICH_DATA CI_END="1.1581519430293639" CI_START="0.1880390384772305" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.06376554012578557" LOG_CI_START="-0.7257519782086344" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="391" O_E="0.0" SE="0.4637664984443843" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="0.2150793650793651" WEIGHT="18.371757925072046"/>
<DICH_DATA CI_END="0.7554877430902458" CI_START="0.34753642404032603" EFFECT_SIZE="0.5124056094929881" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="-0.12177257719054393" LOG_CI_START="-0.4589996718487172" LOG_EFFECT_SIZE="-0.29038612451963053" ORDER="392" O_E="0.0" SE="0.19808886470325168" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.03923919831942315" WEIGHT="81.62824207492795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9175807991232323" CI_START="0.6380954815670732" DF="0.0" EFFECT_SIZE="1.106164383561644" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="8" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.282753672424963" LOG_CI_START="-0.1951143306595937" LOG_EFFECT_SIZE="0.04381967088268463" NO="2" P_CHI2="1.0" P_Z="0.7192580074163292" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="17" WEIGHT="100.0" Z="0.3594506273284147">
<NAME>any reason - short term</NAME>
<DICH_DATA CI_END="1.9175807991232323" CI_START="0.6380954815670732" EFFECT_SIZE="1.106164383561644" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="8" LOG_CI_END="0.282753672424963" LOG_CI_START="-0.1951143306595937" LOG_EFFECT_SIZE="0.04381967088268463" ORDER="393" O_E="0.0" SE="0.28070203049663395" STUDY_ID="STD-Goff-1998" TOTAL_1="73" TOTAL_2="17" VAR="0.0787936299249332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6212385166444707" CI_START="0.7344710962072227" DF="0.0" EFFECT_SIZE="1.0912162162162162" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.20984691296223532" LOG_CI_START="-0.13402529041790665" LOG_EFFECT_SIZE="0.037910811272164315" NO="3" P_CHI2="1.0" P_Z="0.6656254726621238" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.43215952896312576">
<NAME>any reason - long term</NAME>
<DICH_DATA CI_END="1.6212385166444707" CI_START="0.7344710962072227" EFFECT_SIZE="1.0912162162162162" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.20984691296223532" LOG_CI_START="-0.13402529041790665" LOG_EFFECT_SIZE="0.037910811272164315" ORDER="394" O_E="0.0" SE="0.20199223446035477" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.04080086278228693" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5317091430054828" CI_END="2.8140424662450534" CI_START="0.24971015704001254" DF="1.0" EFFECT_SIZE="0.8382690416347942" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="71.68509751205048" ID="CMP-002.09.04" LOG_CI_END="0.44933064701369996" LOG_CI_START="-0.6025637922232766" LOG_EFFECT_SIZE="-0.07661657260478835" NO="4" P_CHI2="0.06020583683387282" P_Z="0.7752497564576453" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="142" WEIGHT="100.0" Z="0.28551481464853184">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="23.867941444301437" CI_START="0.3554291936738945" EFFECT_SIZE="2.912621359223301" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3778149637100208" LOG_CI_START="-0.44924690368104025" LOG_EFFECT_SIZE="0.46428403001449026" ORDER="100" O_E="0.0" SE="1.0732251850076142" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="1.151812297734628" WEIGHT="24.762321057807892"/>
<DICH_DATA CI_END="1.4514829013521908" CI_START="0.0166709031444017" EFFECT_SIZE="0.15555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.16181192415520196" LOG_CI_START="-1.7780408716773755" LOG_EFFECT_SIZE="-0.8081144737610868" ORDER="395" O_E="0.0" SE="1.1394791346982613" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="1.2984126984126985" WEIGHT="75.2376789421921"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4514829013521908" CI_START="0.0166709031444017" DF="0.0" EFFECT_SIZE="0.15555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.09.05" LOG_CI_END="0.16181192415520196" LOG_CI_START="-1.7780408716773755" LOG_EFFECT_SIZE="-0.8081144737610868" NO="5" P_CHI2="1.0" P_Z="0.10247215037365624" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="142" WEIGHT="100.0" Z="1.6329850052127028">
<NAME>due to lack of efficacy</NAME>
<DICH_DATA CI_END="1.4514829013521908" CI_START="0.0166709031444017" EFFECT_SIZE="0.15555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.16181192415520196" LOG_CI_START="-1.7780408716773755" LOG_EFFECT_SIZE="-0.8081144737610868" ORDER="397" O_E="0.0" SE="1.1394791346982613" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="1.2984126984126985" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="398" O_E="0.0" SE="0.0" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9780966427520849" CI_END="0.979353027091537" CI_START="0.7850202063884177" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8768192034020013" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="155" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-0.00906072997285795" LOG_CI_START="-0.10511916438844524" LOG_EFFECT_SIZE="-0.0570899471806516" METHOD="MH" NO="10" P_CHI2="0.32266938341631246" P_Q="0.0" P_Z="0.01982138154447959" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="238" TOTAL_2="195" WEIGHT="200.0" Z="2.32971193074565">
<NAME>Side effects 1: Any adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0714550806104945" CI_START="0.5466725779837364" DF="0.0" EFFECT_SIZE="0.7653333333333333" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="25" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.029973968516516552" LOG_CI_START="-0.26227271050396955" LOG_EFFECT_SIZE="-0.11614937099372653" NO="1" P_CHI2="1.0" P_Z="0.11925203359726444" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="42" WEIGHT="100.0" Z="1.5579207588444652">
<NAME>immediate term</NAME>
<DICH_DATA CI_END="1.0714550806104945" CI_START="0.5466725779837364" EFFECT_SIZE="0.7653333333333333" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="25" LOG_CI_END="0.029973968516516552" LOG_CI_START="-0.26227271050396955" LOG_EFFECT_SIZE="-0.11614937099372653" ORDER="399" O_E="0.0" SE="0.17166714590102589" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="0.029469608981804105" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0123432509274994" CI_START="0.8118104492296319" DF="0.0" EFFECT_SIZE="0.9065488565488565" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="130" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.005327791859770498" LOG_CI_START="-0.09054536295521604" LOG_EFFECT_SIZE="-0.042608785547722766" NO="2" P_CHI2="1.0" P_Z="0.08148593459484114" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.742128654464037">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.0123432509274994" CI_START="0.8118104492296319" EFFECT_SIZE="0.9065488565488565" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="130" LOG_CI_END="0.005327791859770498" LOG_CI_START="-0.09054536295521604" LOG_EFFECT_SIZE="-0.042608785547722766" ORDER="400" O_E="0.0" SE="0.05631636571809333" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.0031715330476940378" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6172255506646955" CI_END="1.747028122546153" CI_START="0.6430650313723514" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.059930513964723" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="23" I2="38.165706101477916" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.2422998960351968" LOG_CI_START="-0.19174510586573346" LOG_EFFECT_SIZE="0.025277395084731664" METHOD="MH" NO="11" P_CHI2="0.2034791358558391" P_Q="0.0" P_Z="0.819425393091706" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="354" TOTAL_2="253" WEIGHT="200.0" Z="0.22828408930911676">
<NAME>Side effects 2: Cardiovascular problems - dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3578950329607236" CI_START="0.7244200731015835" DF="0.0" EFFECT_SIZE="1.3069454817027633" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.3725244675866276" LOG_CI_START="-0.14000952423805663" LOG_EFFECT_SIZE="0.11625747167428545" NO="1" P_CHI2="1.0" P_Z="0.3739211002382723" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="100.0" Z="0.8891525676338994">
<NAME>immediate term</NAME>
<DICH_DATA CI_END="2.3578950329607236" CI_START="0.7244200731015835" EFFECT_SIZE="1.3069454817027633" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" LOG_CI_END="0.3725244675866276" LOG_CI_START="-0.14000952423805663" LOG_EFFECT_SIZE="0.11625747167428545" ORDER="401" O_E="0.0" SE="0.30106500388199664" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.09064013656246667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6635813169605993" CI_START="0.2312692528214214" DF="0.0" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.2210440343266547" LOG_CI_START="-0.6358821027140847" LOG_EFFECT_SIZE="-0.20741903419371496" NO="2" P_CHI2="1.0" P_Z="0.3427127637029863" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.00000000000001" Z="0.9488188518363191">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.6635813169605993" CI_START="0.2312692528214214" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2210440343266547" LOG_CI_START="-0.6358821027140847" LOG_EFFECT_SIZE="-0.20741903419371496" ORDER="402" O_E="0.0" SE="0.5033626547505204" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.25337396219749164" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.289018918363868" CI_END="4.288853216238861" CI_START="1.7578364425441144" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.745742609974067" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="23" I2="22.42161959350568" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.6323411829916161" LOG_CI_START="0.24497846379517924" LOG_EFFECT_SIZE="0.43865982339339765" METHOD="MH" NO="12" P_CHI2="0.25622894301792276" P_Q="0.0" P_Z="9.036502711718529E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="354" TOTAL_2="253" WEIGHT="200.0" Z="4.439030462710923">
<NAME>Side effects 3: Gastrointestinal problems</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8792942696591015E-31" CI_END="7.2003097398014155" CI_START="1.780075527057884" DF="0.0" EFFECT_SIZE="3.58009708737864" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="8" I2="100.0" ID="CMP-002.12.01" LOG_CI_END="0.8573511791247704" LOG_CI_START="0.25043842943732375" LOG_EFFECT_SIZE="0.5538948042810472" NO="1" P_CHI2="0.0" P_Z="3.469019616365241E-4" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="99.99999999999999" Z="3.577495671902736">
<NAME>immediate term</NAME>
<DICH_DATA CI_END="7.200309739801417" CI_START="1.7800755270578845" EFFECT_SIZE="3.5800970873786406" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="8" LOG_CI_END="0.8573511791247705" LOG_CI_START="0.25043842943732386" LOG_EFFECT_SIZE="0.5538948042810472" ORDER="403" O_E="0.0" SE="0.35650355343296936" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.12709478361033405" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.791288519246881" CI_START="1.2039638987554817" DF="0.0" EFFECT_SIZE="2.1364864864864863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.5787868357450663" LOG_CI_START="0.08061346465739937" LOG_EFFECT_SIZE="0.32970015020123283" NO="2" P_CHI2="1.0" P_Z="0.00947894622392935" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="2.5942792513417836">
<NAME>long term</NAME>
<DICH_DATA CI_END="3.791288519246881" CI_START="1.2039638987554817" EFFECT_SIZE="2.1364864864864863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" LOG_CI_END="0.5787868357450663" LOG_CI_START="0.08061346465739937" LOG_EFFECT_SIZE="0.32970015020123283" ORDER="404" O_E="0.0" SE="0.29262950417485356" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.08563202671362063" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.880445537585226" CI_END="0.3432749777051392" CI_START="0.18598817885319166" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25267585549325605" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="104" I2="29.152992409380815" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.464357852387352" LOG_CI_START="-0.7305146580507696" LOG_EFFECT_SIZE="-0.5974362552190609" METHOD="MH" NO="13" P_CHI2="0.19545050125763475" P_Q="0.0" P_Z="1.3807140223682654E-18" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1184" TOTAL_2="568" WEIGHT="500.0" Z="8.798975028041394">
<NAME>Side effects 4a: Movement disorders - immediate term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3795312323098012" CI_END="0.5876320871781872" CI_START="0.1958167277246295" DF="1.0" EFFECT_SIZE="0.3392170284894713" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="-0.23089449793290928" LOG_CI_START="-0.7081502111631411" LOG_EFFECT_SIZE="-0.4695223545480253" NO="1" P_CHI2="0.5378545369178397" P_Z="1.1506433147182705E-4" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="142" WEIGHT="100.0" Z="3.856410219259717">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="0.8881133180929126" CI_START="0.061303488344658055" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="-0.0515316172364384" LOG_CI_START="-1.2125148121743727" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="405" O_E="0.0" SE="0.6819672756660433" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="0.4650793650793651" WEIGHT="22.442792880891844"/>
<DICH_DATA CI_END="0.6772618702276401" CI_START="0.2019809030314167" EFFECT_SIZE="0.36985668053629217" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="-0.1692433744392225" LOG_CI_START="-0.6946896904550733" LOG_EFFECT_SIZE="-0.4319665324471479" ORDER="406" O_E="0.0" SE="0.30864976702892355" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.09526467868700879" WEIGHT="77.55720711910816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.040432283753452536" CI_END="0.8494044316142532" CI_START="0.2032745967966069" DF="1.0" EFFECT_SIZE="0.4155265856159367" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="-0.07088547748638555" LOG_CI_START="-0.6919168917032841" LOG_EFFECT_SIZE="-0.38140118459483485" NO="2" P_CHI2="0.8406378358342395" P_Z="0.01606697648899838" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="142" WEIGHT="100.0" Z="2.4073905710853767">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="1.3197675162807354" CI_START="0.10560782566505442" EFFECT_SIZE="0.37333333333333335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.12049743477497304" LOG_CI_START="-0.9763038988739348" LOG_EFFECT_SIZE="-0.4279032320494808" ORDER="407" O_E="0.0" SE="0.6442665326395319" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="0.41507936507936505" WEIGHT="33.61652263073092"/>
<DICH_DATA CI_END="1.04103423253995" CI_START="0.183351964453542" EFFECT_SIZE="0.4368932038834951" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.017465010738933646" LOG_CI_START="-0.7367144325985906" LOG_EFFECT_SIZE="-0.35962471092982856" ORDER="408" O_E="0.0" SE="0.4430087382649153" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.19625674217907227" WEIGHT="66.38347736926907"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8038835904895496" CI_END="0.19447745327172233" CI_START="0.030782401353127913" DF="1.0" EFFECT_SIZE="0.0773723660019799" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="31" I2="44.56405029281221" ID="CMP-002.13.03" LOG_CI_END="-0.7111307413165087" LOG_CI_START="-1.5116975036165252" LOG_EFFECT_SIZE="-1.111414122466517" NO="3" P_CHI2="0.17924384276219463" P_Z="5.269344238419882E-8" STUDIES="2" TAU2="0.0" TOTAL_1="296" TOTAL_2="142" WEIGHT="99.99999999999999" Z="5.44197374791141">
<NAME>extrapyrimidal side effects</NAME>
<DICH_DATA CI_END="0.21268962593528978" CI_START="0.003999698813252254" EFFECT_SIZE="0.029166666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="16" LOG_CI_END="-0.6722536925558208" LOG_CI_START="-2.3979727108388778" LOG_EFFECT_SIZE="-1.5351132016973492" ORDER="409" O_E="0.0" SE="1.0136958937863787" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="1.0275793650793652" WEIGHT="51.93042002545608"/>
<DICH_DATA CI_END="0.37995301965833606" CI_START="0.04410350685432342" EFFECT_SIZE="0.12944983818770225" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.42027009960556355" LOG_CI_START="-1.355526876588181" LOG_EFFECT_SIZE="-0.8878984880968723" ORDER="410" O_E="0.0" SE="0.5493744603953007" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.3018122977346278" WEIGHT="48.069579974543906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.617929793495596" CI_START="0.07879180731588718" DF="0.0" EFFECT_SIZE="0.22065313327449249" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-002.13.04" LOG_CI_END="-0.20906086476470925" LOG_CI_START="-1.10351893761801" LOG_EFFECT_SIZE="-0.6562899011913597" NO="4" P_CHI2="1.0" P_Z="0.0040253903558258005" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="100.0" Z="2.8761651524909015">
<NAME>hypertonia</NAME>
<DICH_DATA CI_END="0.617929793495596" CI_START="0.07879180731588718" EFFECT_SIZE="0.22065313327449249" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="-0.20906086476470925" LOG_CI_START="-1.10351893761801" LOG_EFFECT_SIZE="-0.6562899011913597" ORDER="411" O_E="0.0" SE="0.5254090996328975" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.27605472197705205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5496747344916223" CI_START="0.16739192350947227" DF="0.0" EFFECT_SIZE="0.30333333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-002.13.05" LOG_CI_END="-0.25989422469161627" LOG_CI_START="-0.7762655001055214" LOG_EFFECT_SIZE="-0.5180798623985688" NO="5" P_CHI2="1.0" P_Z="8.3927731059411E-5" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="42" WEIGHT="100.0" Z="3.9328983611752553">
<NAME>use of anti-cholinergic medication</NAME>
<DICH_DATA CI_END="0.5496747344916223" CI_START="0.16739192350947227" EFFECT_SIZE="0.30333333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.25989422469161627" LOG_CI_START="-0.7762655001055214" LOG_EFFECT_SIZE="-0.5180798623985688" ORDER="412" O_E="0.0" SE="0.3033190432571651" STUDY_ID="STD-Brook-1998" TOTAL_1="90" TOTAL_2="42" VAR="0.092002442002442" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.246276614911123" CI_END="0.5770986598444205" CI_START="0.31952892632511143" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4294178794178794" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="130" I2="39.366574352370435" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-0.2387499342216593" LOG_CI_START="-0.4954898199007945" LOG_EFFECT_SIZE="-0.36711987706122684" METHOD="MH" NO="14" P_CHI2="0.14317515331497088" P_Q="0.0" P_Z="2.079909243431091E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="888" TOTAL_2="918" WEIGHT="600.0" Z="5.605219735495527">
<NAME>Side effects 4b: Movement disorders - long term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.597511854664999" CI_START="0.4978371054326139" DF="0.0" EFFECT_SIZE="1.1371621621621621" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.4145575382903683" LOG_CI_START="-0.30291273712863537" LOG_EFFECT_SIZE="0.055822400580866446" NO="1" P_CHI2="1.0" P_Z="0.7603753294195789" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.00000000000001" Z="0.3049879511877214">
<NAME>agitation</NAME>
<DICH_DATA CI_END="2.597511854664999" CI_START="0.4978371054326139" EFFECT_SIZE="1.1371621621621621" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4145575382903683" LOG_CI_START="-0.30291273712863537" LOG_EFFECT_SIZE="0.055822400580866446" ORDER="413" O_E="0.0" SE="0.4214455913162645" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.17761638643991587" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6487796876169807" CI_START="0.12914519407708025" DF="0.0" EFFECT_SIZE="0.28945945945945944" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="-0.18790275573579285" LOG_CI_START="-0.8889217507344858" LOG_EFFECT_SIZE="-0.5384122532351394" NO="2" P_CHI2="1.0" P_Z="0.0026067150224092844" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="3.0106705601547925">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="0.6487796876169807" CI_START="0.12914519407708025" EFFECT_SIZE="0.28945945945945944" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.18790275573579285" LOG_CI_START="-0.8889217507344858" LOG_EFFECT_SIZE="-0.5384122532351394" ORDER="414" O_E="0.0" SE="0.4117820277622225" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.16956443838796778" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3987766030521627" CI_START="0.06236989067081002" DF="0.0" EFFECT_SIZE="0.2953667953667954" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-002.14.03" LOG_CI_END="0.1457483593747535" LOG_CI_START="-1.2050250172300216" LOG_EFFECT_SIZE="-0.5296383289276342" NO="3" P_CHI2="1.0" P_Z="0.124292326916334" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.5370040119377817">
<NAME>extrapyrimidal side effects</NAME>
<DICH_DATA CI_END="1.3987766030521622" CI_START="0.06236989067081002" EFFECT_SIZE="0.2953667953667954" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14574835937475336" LOG_CI_START="-1.2050250172300216" LOG_EFFECT_SIZE="-0.5296383289276342" ORDER="415" O_E="0.0" SE="0.7934509678536965" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.6295644383879677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9904307140765262" CI_START="0.08025876455789321" DF="0.0" EFFECT_SIZE="0.2819410319410319" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" ID="CMP-002.14.04" LOG_CI_END="-0.004175900283646332" LOG_CI_START="-1.0955075297481962" LOG_EFFECT_SIZE="-0.5498417150159212" NO="4" P_CHI2="1.0" P_Z="0.04827231288422625" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.9749633008578504">
<NAME>hypertonia</NAME>
<DICH_DATA CI_END="0.9904307140765264" CI_START="0.08025876455789321" EFFECT_SIZE="0.2819410319410319" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.004175900283646235" LOG_CI_START="-1.0955075297481962" LOG_EFFECT_SIZE="-0.5498417150159212" ORDER="416" O_E="0.0" SE="0.6410536013261677" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.4109497197732492" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5643048931070157" CI_START="0.2384556391841462" DF="0.0" EFFECT_SIZE="0.3668265039232781" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="62" I2="0.0" ID="CMP-002.14.05" LOG_CI_END="-0.24848618393133545" LOG_CI_START="-0.6225924025754771" LOG_EFFECT_SIZE="-0.43553929325340623" NO="5" P_CHI2="1.0" P_Z="5.027646470898709E-6" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="4.563630787654501">
<NAME>movement disorders - unspecified</NAME>
<DICH_DATA CI_END="0.5643048931070157" CI_START="0.2384556391841462" EFFECT_SIZE="0.3668265039232781" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="62" LOG_CI_END="-0.24848618393133545" LOG_CI_START="-0.6225924025754771" LOG_EFFECT_SIZE="-0.43553929325340623" ORDER="417" O_E="0.0" SE="0.2197518446872174" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.048290873243434916" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3734116522608557" CI_START="0.28013102083983216" DF="0.0" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-002.14.06" LOG_CI_END="0.13780072770295437" LOG_CI_START="-0.5526387960903844" LOG_EFFECT_SIZE="-0.20741903419371496" NO="6" P_CHI2="1.0" P_Z="0.23895261245855137" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.17760882081092">
<NAME>tremor</NAME>
<DICH_DATA CI_END="1.3734116522608557" CI_START="0.28013102083983216" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.13780072770295437" LOG_CI_START="-0.5526387960903844" LOG_EFFECT_SIZE="-0.20741903419371496" ORDER="418" O_E="0.0" SE="0.40556759400697034" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.1644850733086027" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.15" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Side effects 4c. Movement disorders scores (AIMS endpoint scores - long term - skewed data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="139" STUDY_ID="STD-Hirsch-1999">
<TR>
<TD>
<P>Zip 80mg: n=101, mean endpoint = 0.87, SD = 2.033.<BR/>Haloperidol: n=112, mean endpoint = 1.33, SD = 2.659</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.16" NO="16" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Side effects: 4d. Movement disorders scores (BAS endpoint scores - long term - skewed data)</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="140" STUDY_ID="STD-Hirsch-1999">
<TR>
<TD>
<P>Zip 80mg: n=110, mean endpoint = 0.47, SD = 0.945.<BR/>Haloperidol: n=119, mean endpoint = 0.67, SD = 0.984</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.17" NO="17" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Side effects: 4e. Movement disorders scores (SAS endpoint scores - long term - skewed data).</NAME>
<TR>
<TH/>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="141" STUDY_ID="STD-Hirsch-1999">
<TR>
<TD>
<P>Zip 80mg: n=109, mean endpoint = 3.00, SD = 4.395.<BR/>Haloperidol: n=117, mean endpoint = 3.62, SD = 4.829.</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="1.8277149330735476" CI_END="1.6516074002104904" CI_START="0.8473085705667471" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.182971303713582" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.2179068201117108" LOG_CI_START="-0.07195840066142795" LOG_EFFECT_SIZE="0.07297420972514142" METHOD="MH" NO="18" P_CHI2="0.4009745401754965" P_Q="0.0" P_Z="0.3237159336878289" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="502" TOTAL_2="406" WEIGHT="300.0" Z="0.9868505264623579">
<NAME>Side effects 5: Sleep disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4038648589765907" CI_START="0.6970966169020186" DF="0.0" EFFECT_SIZE="1.2944983818770226" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="12" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="0.38091004875064094" LOG_CI_START="-0.1567070249443856" LOG_EFFECT_SIZE="0.11210151190312771" NO="1" P_CHI2="1.0" P_Z="0.4137193766651671" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="100.0" Z="0.8173658787751074">
<NAME>insomnia - immediate term</NAME>
<DICH_DATA CI_END="2.4038648589765907" CI_START="0.6970966169020186" EFFECT_SIZE="1.2944983818770226" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="12" LOG_CI_END="0.38091004875064094" LOG_CI_START="-0.1567070249443856" LOG_EFFECT_SIZE="0.11210151190312771" ORDER="422" O_E="0.0" SE="0.31579893033589346" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.0997289644012945" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.516969589756529" CI_START="0.5566439731218616" DF="0.0" EFFECT_SIZE="0.918918918918919" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" I2="0.0" ID="CMP-002.18.02" LOG_CI_END="0.18097687470017126" LOG_CI_START="-0.25442248874965095" LOG_EFFECT_SIZE="-0.036722807024739845" NO="2" P_CHI2="1.0" P_Z="0.7409332367331194" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.33061775106614016">
<NAME>insomnia - long term</NAME>
<DICH_DATA CI_END="1.5169695897565287" CI_START="0.5566439731218616" EFFECT_SIZE="0.918918918918919" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.18097687470017118" LOG_CI_START="-0.25442248874965095" LOG_EFFECT_SIZE="-0.036722807024739845" ORDER="423" O_E="0.0" SE="0.2557557413520342" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.06541099923452863" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.079277128656146" CI_START="0.8214553099686365" DF="0.0" EFFECT_SIZE="1.5904365904365905" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-002.18.03" LOG_CI_END="0.4884487762790041" LOG_CI_START="-0.08541605871943238" LOG_EFFECT_SIZE="0.20151635877978585" NO="3" P_CHI2="1.0" P_Z="0.1686643719762317" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.3765081301944853">
<NAME>somnolence - long term</NAME>
<DICH_DATA CI_END="3.0792771286561456" CI_START="0.8214553099686366" EFFECT_SIZE="1.5904365904365905" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.48844877627900407" LOG_CI_START="-0.08541605871943232" LOG_EFFECT_SIZE="0.20151635877978585" ORDER="424" O_E="0.0" SE="0.3370910447548286" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.11363037245390185" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.358528561706041" CI_END="2.903201942287392" CI_START="1.2153815933333942" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8784297171802449" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="23" I2="54.11295413842262" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.46287724574238104" LOG_CI_START="0.08471265477395204" LOG_EFFECT_SIZE="0.2737949502581665" METHOD="MH" NO="19" P_CHI2="0.11312481064764823" P_Q="0.0" P_Z="0.004538764035224155" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="618" TOTAL_2="300" WEIGHT="300.0" Z="2.8380670981421545">
<NAME>Side effects 6a: Other problems - immediate term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1745299674070138" CI_START="0.6566189528625861" DF="0.0" EFFECT_SIZE="1.1949215832710978" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="0.3373653970966982" LOG_CI_START="-0.18268658580886674" LOG_EFFECT_SIZE="0.07733940564391578" NO="1" P_CHI2="1.0" P_Z="0.559926191511899" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="100.0" Z="0.5829511457716497">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="2.174529967407014" CI_START="0.6566189528625861" EFFECT_SIZE="1.1949215832710978" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.3373653970966983" LOG_CI_START="-0.18268658580886674" LOG_EFFECT_SIZE="0.07733940564391578" ORDER="425" O_E="0.0" SE="0.30548110905756204" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.0933187079910381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.406955159714901" CI_START="1.023488676954819" DF="0.0" EFFECT_SIZE="2.1237864077669903" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" I2="0.0" ID="CMP-002.19.02" LOG_CI_END="0.6441386316337089" LOG_CI_START="0.010083042344648418" LOG_EFFECT_SIZE="0.32711083698917864" NO="2" P_CHI2="1.0" P_Z="0.043145319678572325" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="99.99999999999999" Z="2.022300474223118">
<NAME>headache</NAME>
<DICH_DATA CI_END="4.406955159714902" CI_START="1.023488676954819" EFFECT_SIZE="2.1237864077669903" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.644138631633709" LOG_CI_START="0.010083042344648418" LOG_EFFECT_SIZE="0.32711083698917864" ORDER="426" O_E="0.0" SE="0.3724473917741803" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.13871705963938974" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.261801732790445" CI_START="1.2808274277861869" DF="0.0" EFFECT_SIZE="5.339805825242719" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" I2="0.0" ID="CMP-002.19.03" LOG_CI_END="1.3475603105352234" LOG_CI_START="0.10749061904291979" LOG_EFFECT_SIZE="0.7275254647890717" NO="3" P_CHI2="1.0" P_Z="0.021462518160744803" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="100" WEIGHT="99.99999999999999" Z="2.2997476974159134">
<NAME>pain at injection site</NAME>
<DICH_DATA CI_END="22.261801732790452" CI_START="1.2808274277861869" EFFECT_SIZE="5.339805825242719" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.3475603105352236" LOG_CI_START="0.10749061904291979" LOG_EFFECT_SIZE="0.7275254647890717" ORDER="427" O_E="0.0" SE="0.7284230752265517" STUDY_ID="STD-Swift-1998" TOTAL_1="206" TOTAL_2="100" VAR="0.5306001765225066" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6554394860924058" CI_END="1.2626586817652856" CI_START="0.5877748097064844" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8614864864864865" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.10128596919427668" LOG_CI_START="-0.2307890304442435" LOG_EFFECT_SIZE="-0.0647515306249834" METHOD="MH" NO="20" P_CHI2="0.45464020321331045" P_Q="0.0" P_Z="0.44465904378495424" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="740" TOTAL_2="765" WEIGHT="500.0" Z="0.7643494277314357">
<NAME>Side effects 6b: Other problems - long term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.31133947211246" CI_START="0.4623764377794168" DF="0.0" EFFECT_SIZE="1.0337837837837838" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="0.3638637360623653" LOG_CI_START="-0.33500430521708247" LOG_EFFECT_SIZE="0.014429715422641409" NO="1" P_CHI2="1.0" P_Z="0.9354930078628432" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.08093580151057635">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="2.31133947211246" CI_START="0.4623764377794168" EFFECT_SIZE="1.0337837837837838" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3638637360623653" LOG_CI_START="-0.33500430521708247" LOG_EFFECT_SIZE="0.014429715422641409" ORDER="428" O_E="0.0" SE="0.4105185469001453" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.16852547734900677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6850259822173954" CI_START="0.6525313695848877" DF="0.0" EFFECT_SIZE="1.5506756756756757" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-002.20.02" LOG_CI_END="0.5664405543100939" LOG_CI_START="-0.1853986053534487" LOG_EFFECT_SIZE="0.19052097447832264" NO="2" P_CHI2="1.0" P_Z="0.32054651609853446" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.9933354587278874">
<NAME>asthenia</NAME>
<DICH_DATA CI_END="3.6850259822173954" CI_START="0.6525313695848877" EFFECT_SIZE="1.5506756756756757" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5664405543100939" LOG_CI_START="-0.1853986053534487" LOG_EFFECT_SIZE="0.19052097447832264" ORDER="429" O_E="0.0" SE="0.4416340440502275" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.19504062886415827" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9818242487107807" CI_START="0.3609889776518578" DF="0.0" EFFECT_SIZE="0.8458230958230958" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" ID="CMP-002.20.03" LOG_CI_END="0.29706513793965483" LOG_CI_START="-0.4425060585321724" LOG_EFFECT_SIZE="-0.07272046029625877" NO="3" P_CHI2="1.0" P_Z="0.6999128105777856" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.38543816687234">
<NAME>depression</NAME>
<DICH_DATA CI_END="1.9818242487107807" CI_START="0.3609889776518578" EFFECT_SIZE="0.8458230958230958" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.29706513793965483" LOG_CI_START="-0.4425060585321724" LOG_EFFECT_SIZE="-0.07272046029625877" ORDER="430" O_E="0.0" SE="0.43442778174401664" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.18872749755102694" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6800811417750505" CI_START="0.15902638346461018" DF="0.0" EFFECT_SIZE="0.5168918918918919" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-002.20.04" LOG_CI_END="0.2253302570676336" LOG_CI_START="-0.7985308175503132" LOG_EFFECT_SIZE="-0.28660028024133977" NO="4" P_CHI2="1.0" P_Z="0.2725232219681133" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.0972704034904743">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="1.6800811417750505" CI_START="0.15902638346461018" EFFECT_SIZE="0.5168918918918919" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.2253302570676336" LOG_CI_START="-0.7985308175503132" LOG_EFFECT_SIZE="-0.28660028024133977" ORDER="431" O_E="0.0" SE="0.6014210634246401" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.361707295530825" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2745928455218303" CI_START="0.26529740870075835" DF="0.0" EFFECT_SIZE="0.5815033783783784" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-002.20.05" LOG_CI_END="0.10537147639152443" LOG_CI_START="-0.5762669919794413" LOG_EFFECT_SIZE="-0.2354477577939585" NO="5" P_CHI2="1.0" P_Z="0.17573648777924758" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.3539996550362665">
<NAME>headache</NAME>
<DICH_DATA CI_END="1.2745928455218303" CI_START="0.26529740870075835" EFFECT_SIZE="0.5815033783783784" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.10537147639152443" LOG_CI_START="-0.5762669919794413" LOG_EFFECT_SIZE="-0.2354477577939585" ORDER="432" O_E="0.0" SE="0.40039781048594164" STUDY_ID="STD-Hirsch-1999" TOTAL_1="148" TOTAL_2="153" VAR="0.16031840664193606" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>